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D. SUMMARY 
 
A retrospective study was conducted to analyse the treatment responses in HIV+ and 
HIV- patients that were treated with the same standard of radical treatment for FIGO 
stage II and III Ca Cx, at DROUAH. The main objective of the study was to determine 
how the HIV+ patients tolerated their treatment. The secondary objective was to 
retrospectively analyse the overall outcomes and therapeutic benefits of the treatment 
in terms of quality of life and tumour responses amongst the HIV+ patients. General 
condition of patients, adverse responses to treatment, and tumour responses were 
used as indicators of overall outcomes and therapeutic benefits of the treatment. The 
HIV- patients were included in the study to benchmark the therapeutic benefits in 
terms of quality of life and tumour response.   
 
Ninety six (96) patients who were treated with radical intent for FIGO stage II and III 
Ca Cx at DROUAH were included in the study. The patients that were included in the 
study received treatment between January 2002 and August 2006. All the patients that 
were included in the study were treated using a combination of EBRT, HDR-ICBT and 
concurrent chemotherapy. The EBRT was given in daily fractions of 2 Gy to a total of 
50 Gy. The HDR-ICBT was given in 4 to 6 weekly fractions varying between 2.0 Gy 
and 2.5 Gy per fraction, to a minimum total dose of 15 Gy to point A. Five weekly 
cycles of Cisplatin were given as the chemotherapeutic agent. 
 
The data that was used for the current study constituted oncologists’ and other 
medical staff reports in the patients’ treatment files. An electronic Excel® data source 
form was used as the research tool to collect data from the eligible patients’ treatment 
files. The data was processed and analysed by statisticians at the department of 
Biostatistics at the UFS. The Fisher's exact- and the Chi-squared tests were used to 
analyse the data.  
 
Although the focus of the current study was not to compare the HIV+ and HIV- 
patients, parallel analyses of the two groups were conducted. From the 96 patients 
 ix 
that were included in the data sub-analysis, there were 19 reported deaths, 
representing an 18-month overall survival rate of 80.2%.  Twelve of the 19 reported 
deaths were HIV+ patients, whilst the remaining seven were HIV-. This implies a 
67.6% 18-month overall survival rate for HIV+ patients, and an 88.1% rate for HIV- 
patients in the study.  
 
From this retrospective analysis it can be concluded that HIV+ patients treated at 
DROUAH for FIGO stage II and III Ca Cx with radical intent do not tolerate their 
treatment as well as their HIV- counterparts. The tumour responses of HIV+ patients 
were analysed, with HIV- patients used to benchmark the therapeutic benefits in terms 
of quality of life and tumour response. The study results suggest that the overall 
quality of life of HIV+ patients was more adversely affected than that of HIV- patients, 
in terms of both general condition and the adverse responses that were reported.  
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1. CHAPTER 1: INTRODUCTION AND BACKGROUND 
 
1.1 INTRODUCTION 
 
The successful treatment and management of cancer continue to pose 
challenges to both researchers and oncologists (Symonds 2001:1107). The 
success of cancer treatment is determined by the extent to which local tumour 
control is accomplished, while damage to surrounding normal tissue and quality 
of life are simultaneously limited to a minimum (International Commission on 
Radiation Units and Measurements, ICRU 1985). Medical scientists continue to 
engage in research aimed at improving the available treatment for cancer in 
order to enhance cancer cure rates (Jemal 2002:23). Such improvements in the 
treatment and management of cancer will lead to enhanced local tumour control, 
improved survival rates and a higher quality of life for patients (Symonds 
2001:1107). 
 
According to the December 2006 AIDS Epidemic Update released by the United 
Nations Joint Programme on HIV/AIDS (UNAIDS), more than 15 million Africans 
have died from conditions related to the Human Immunodeficiency Virus (HIV) 
and the Acquired Immune Deficiency Syndrome (AIDS) [HIV/AIDS] over the past 
three decades. It is expected that the impact of HIV/AIDS will remain severe for 
many years to come (UNAIDS 2006). This expectation poses challenges to the 
health sector [World Health Organisation (WHO) 2008], which relate to physical, 
financial and human resources (WHO 2008). HIV/AIDS also has important 
effects on society, the economy and politics (Barnett and Whiteside 2002:6). The 
negative impact of the HIV/AIDS epidemic is not only experienced by those 
countries severely and directly affected by the epidemic, but by the entire 
international community (UNAIDS 2006). 
 
Marco (1999:2) states that cancer has been around forever, but the conditions 
related to the Human Immunodeficiency Virus and the Acquired Immune 
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Deficiency Syndrome (HIV/AIDS) are relatively new. Most of the attitudes 
expressed in the face of HIV/AIDS and cancer relate to fear and hopelessness. 
Whether they are based on perceptions or facts, these attitudes are largely 
influenced by the morbidity and high death rates commonly associated with these 
conditions. The treatment and management of cancer pose challenges to 
patients and the team involved in treating such patients. Thus, it would seem that 
patients who are diagnosed as having both cancer and HIV/AIDS are confronted 
with complex health challenges.  
 
This study investigates the treatment responses of patients who were treated 
with curative or radical intent for cancer of the uterine cervix (Ca Cx) at the 
Department of Radiation Oncology at the Universitas Annexe Hospital in 
Bloemfontein. (For the purposes of this study the Department of Radiation 
Oncology at the Universitas Annexe hospital in Bloemfontein will be denoted by 
the following acronym: DROUAH.) The study focuses on the effect HIV infection 
has on the patients’ tolerance of the radical treatment approach.  
 
Chapter 1 provides background on key aspects relating to the study, which 
include Ca Cx, DROUAH and HIV/AIDS. The chapter concludes with the 
rationale, aims and objectives of the study, as well as the motivation and 
significance of the study. Background to Ca Cx is dealt with first. 
 
1.2 BACKGROUND TO CA CX 
 
Uterine cervical carcinoma, better known as cervix cancer (Ca Cx), develops in 
the lining of the cervix, which is the lower part of the uterus that enters the vagina 
(Graham, Sotto, and Paoloucek 1988:19). Ca Cx usually develops over time, with 
normal cervical cells gradually mutating or undergoing changes; and then it 
grows out of control to become pre-cancerous and then cancerous (Piver 
1996:79).  
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Cervical intra-epithelial neoplasia (CIN) is the term used to describe the 
abnormal changes that take place in cervical cells (Graham et al. 1988:19). 
Graham, Sotto and Paoloucek (1988:42) classify CIN according to the degree of 
cell abnormality, with low-grade CIN indicating a minimal change in the cells and 
high-grade CIN indicating a greater degree of abnormality. CIN may progress to 
a squamous intra-epithelial lesion (SIL) or to carcinoma-in-situ (Beahrs, Henson, 
Hutter, and Kennedy 1992:156). SIL is a condition that precedes Ca Cx, while 
carcinoma-in-situ is a condition where the carcinoma does not extend beyond the 
epithelial membrane. SIL and carcinoma-in-situ may progress to invasive cervical 
carcinoma, in cases where the carcinoma has spread to healthy tissue. 
 
There are three commonly known types of Ca Cx, namely Squamous cell 
carcinoma, Adenocarcinoma and Adeno-Squamous carcinoma (Chang, Ganz, 
Hayes, Kinsella, Pass, Schiller, Stone and Stretcher 2006:874). Squamous cell 
carcinomas originate from cells that lie on the surface of the cervical lining and 
are the most common cervix cancers, constituting approximately 80% of all Ca 
Cx (Chang et al. 2006:874). Adeno-carcinomas originate from cells in the 
glandular surface of the cervix, and constitute approximately 10-12% of all Ca Cx 
(Chang et al. 2006:874). Adeno-Squamous carcinomas make up about 3-5% of 
Ca Cx, and they have characteristics of both Squamous- and Adeno-carcinomas 
(Chang et al. 2006:874). 
 
1.3 EPIDEMIOLOGY OF CA CX 
 
The origin and development of Ca Cx are unclear (Abraham and Allegra 
2001:212). However, Abraham and Allegra suggest that sexually transmitted 
infection with the human papilloma virus (HPV) is strongly associated with 
cervical and vulvar cancer, and is the most important risk factor for Ca Cx. They 
further state that evidence of HPV is found in nearly 80% of cervical carcinomas. 
HPV is a common sexually transmitted disease, and according to a study 
published in the United States of America (USA) in 2000, 43% of women of 
“college age” were infected in a 3-year period (Bosch, 2002:248). Factors that 
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raise the risk of being infected with HPV include becoming sexually active at an 
early age, having many sexual partners (or having sex with a man who has had 
many partners), and/or having sex with a man who has penile warts (Bosch 
2002:248).  
 
Infection with HIV reduces the immune system's ability to fight infection, including 
HPV infection (Bosch 2002:249). This increases the likelihood that precancerous 
cells will progress to cancer. Because infection with a sexually transmitted 
disease (STD) is a risk factor for Ca Cx, any risk factors for developing STD’s are 
also risk factors for developing Ca Cx (Ellerbrock, Chiasson and Bush 
2000:1033). Sexual activity that increases the risk for infection with HPV and HIV 
and for Ca Cx includes the following: having multiple sexual partners or having 
sex with a promiscuous partner; a history of STD; and sexual intercourse at a 
young age (De Vita, Hellman, and Rosenberg 2004:887).       
 
Infection with HIV, the virus that causes AIDS, is a risk factor for Ca Cx (De Vita, 
et al. 2004:887). These authors state that when a woman is infected with HIV, 
her immune system is less able to fight off early cancers. Women whose immune 
systems have been suppressed by corticosteroid medications, kidney transplants 
or treatments for other types of cancers or AIDS are also at greater risk. 
 
1.4 INCIDENCE OF CA CX   
 
Ca Cx is the sixth most common cancer in women in the world, after carcinoma 
of the breast, lung, colorectum, endometrium and ovary (Perez and Kavanagh 
2004:1800). More than 80% of cases of Ca Cx are reported in underdeveloped 
countries (Stewart and Kleihues 2003:215). Jemal (2002:23) claims that 
approximately 500 000 cases of Ca Cx are diagnosed across the world each 
year, and approximately half (50%) of these cases lead to death. In 2001, the 
American Cancer Society estimated that there were approximately 12 900 new 
cases of Ca Cx in the United States of America (USA), with 4 400 deaths 
resulting from the disease in addition to over 50 000 cases of carcinoma in situ 
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(Perez and Kavanagh 2004:1800). 
 
There is a strong relationship between the incidence of Ca Cx and the standard 
of living in societies (Parkin, Bray and Devesa 2001:554). The disease is more 
common among women of poor socio-economic status, who have a lower 
probability of receiving regular screening and early treatment, (Chang et al. 
2006:874). Ca Cx is more common in middle-aged and older women (Chang et 
al. 2006:874), with an increased incidence among African American, Hispanic 
and Native American women. In 2002, it was reported that there had been a 75% 
decrease in incidence and mortality from Ca Cx in developed nations over the 
past 50 years (Parkin et al. 2001:554). This decrease is mainly due to the 
effective institution of Ca Cx screening programs in wealthier countries (Parkin et 
al. 2001:554). 
 
Whereas developed countries have a low incidence of the disease with high cure 
rates, the patients in underdeveloped countries have a high rate of locally 
advanced disease (Duenas-Gonzalez, Cetina, Sánchez, Gomez, Rivera, 
Hinojosa, López-Graniel, Gonzalez-Enciso and de la Garza 2003:390). These 
locally advanced conditions require a much more aggressive treatment 
approach, with generally poor prospects for survival. Developing countries with a 
high incidence of Ca Cx are Zimbabwe, Uganda, South Africa, Gambia and 
Algeria (Mqoqi, Kellet, Sitas and Jula 2004:22). 
 
1.5 STAGING OF CA CX 
 
Cancer staging represents a core aspect of understanding a patient’s clinical 
condition and planning the most appropriate therapy for each patient (Odicino, 
Miscioscia, Giancarlo, Rampinelli, Sartori and Pecorelli 2007:8). Staging a 
tumour is one of the most important steps in the process of determining the 
prognosis and outcome of a disease (Odicino et al. 2007:8).  
 
The issue of Ca Cx staging dates back to 1928, when the Health Organisation of 
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the League of Nations asked the Radiological Sub-commission of the Cancer 
Commission to explore the possibility of having a uniform statistical report on 
radio-therapeutic results for Ca Cx (Greene, Page, Fleming, Fritz, Balch and 
Haller 2002:47). The Sub-commission reported that this could be accomplished if 
various institutions produce their results in a uniform and consistent manner. 
Accordingly, a group of experts was given the task of producing an appropriate 
classification framework, and subsequently, the first staging system for Ca Cx 
was published in 1929. These recommendations became known as the League 
of Nations Classification for Ca Cx. Since then, eight changes to the staging 
classification have been made, with the International Federation of Gynaecology 
and Obstetrics (FIGO) becoming the main sponsor about 50 years ago (Odicino 
et al. 2007:8).  
 
The FIGO system, a clinical staging system, stages the cancer based on findings 
from clinical examination and evaluation, and basic radiographic studies (Chang 
et al. 2006:877). The examinations include inspection, palpatation, colposcopy 
with biopsy and endocervical curettage, cervical conisation, hysteroscopy, 
intravenous pyelogram and plain films of the chest and bones. The FIGO staging 
system is appropriate for invasive Ca Cx, but not for precancerous lesions 
(Chang et al. 2006:878). Appendix 1 contains a summary of the 2002 FIGO 
staging system as provided by the American Joint Committee on Cancer (AJCC) 
in the AJCC Cancer Staging Manual (De Vita et al. 2004:887). The next section 
presents an overview of the demographics of the DROUAH.  
 
1.6 UNIVERSITAS ANNEXE HOSPITAL  
 
This research study was conducted retrospectively to analyse the treatment 
responses of HIV-positive (HIV+) and HIV-negative (HIV-)                                                
patients who received treatment for Ca Cx with radical intent at DROUAH. 
Bloemfontein is the capital of the Free State province, one of nine provinces in 
the Republic of South Africa. The Free State is surrounded by the Northern 
Cape, Eastern Cape, North West and Gauteng provinces, as well as the 
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Kingdom of Lesotho. DROUAH is one of two oncology departments that serve 
the entire Free State and Northern Cape provinces, parts of the Eastern Cape 
and North West provinces, and the Kingdom of Lesotho. The second oncology 
department is privately owned and primarily caters for patients with medical 
insurance, and was not included in this study.  
 
The regions served by the Bloemfontein oncology facilities constitute a vast 
geographical area, with a predominantly rural population. The population of the 
Free State province alone is estimated at approximately 2.9 million people, with 
85% of these people dependent on public health services (Statistics South Africa, 
2008). The overwhelming dependence (85%) of the population on public health 
services was further justification for exclusion of the private practice from this 
study. The Goldfields region of the Free State, which is well known for its gold 
mining activities, also forms part of the Department’s service area. The 
population of the hospital’s service area includes people with different levels of 
knowledge, experience, beliefs and perceptions regarding cancer and 
healthcare. An already complex situation is further compounded by factors such 
as migrant labour, high levels of illiteracy, lack of information and lack of 
knowledge about the importance of healthy living and general healthcare. 
 
Figures released by the Centre for the Study of AIDS suggest that 30% of 
women who report for antenatal care at the province’s public healthcare facilities 
are HIV+ (Hargreaves, Morison, Kim, Bonell, Porter, Watts, Busza, Phetla and 
Pronyk 2008:114). The socio-economic conditions associated with the mining 
activities in the Goldfields region have been linked to the increasing prevalence 
of HIV/AIDS in the Free State province (Hargreaves et al. 2008:114). The 
Goldfields region accounts for approximately 40% of the HIV+ antenatal cases in 
the Free State (Hargreaves et al. 2008:114). The emergence of HIV/AIDS as an 
epidemic inevitably has an impact on healthcare in the region. The issue of 
HIV/AIDS and its impact on the treatment and management of Ca Cx at 
DROUAH are discussed later on in this chapter. The next section deals with the 
incidence of Ca Cx at DROUAH 
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1.7 INCIDENCE OF CA CX AT THE UNIVERSITAS ANNEXE HOSPITAL 
 
The figures received from the departmental statistician show a high incidence of 
Ca Cx at DROUAH. According to the Department’s statistics, there were 1603 
patients who were registered with a diagnosis of Ca Cx upon admission to the 
Department between January 2002 and August 2006 (Doman 2007). The 
statistics, as received from the departmental statistician for the aforementioned 
period, are summarized in table 1.1.  
 
Table 1.1 Incidence of Ca Cx at the Department of Radiation Oncology, 
Universitas Annexe Hospital, Bloemfontein, January 2002 to 
August 2006 (Doman, 2007) 
Year No. of patients White Black 
2002 388 36 352 
2003 304 24 280 
2004 350 34 316 
2005 338 36 302 
2006 223 19 204 
    Total 1603 149 1454 
    Average (%) 9.3 90.7 
 
 
The proportion of black patients to white patients, as reflected in the 
departmental statistics, seems to concur with the assertions of the authors cited 
in section 1.4 about the following: the relationship between the incidence of Ca 
Cx and the standard of living in societies; the disease being more common 
among women of low socio-economic status; and South Africa being among the 
developing countries with a higher incidence of Ca Cx. 
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1.8 TREATMENT OF CA CX AT UNIVERSITAS ANNEXE HOSPITAL 
 
Ca Cx patients at DROUAH are either treated with curative (radical) or palliative 
intent. Patients are treated with radical intent if they are diagnosed with Ca Cx, 
FIGO stages I to III. Ca Cx Patients are further required to be in a good or fair 
general condition upon referral for treatment. Patients are classified in 
accordance with the index provided in appendix 2. If patients are diagnosed with 
progressive disease such as FIGO stage IV or metastatic disease, or if radical 
treatment options are considered by the oncologists to be ineffective, then such 
patients are treated with palliative intent. If patients are HIV+, they need to have 
a CD4 count of more than 200 CD4 cells per mm of blood, and they also need to 
be in a good general condition. However, HIV+ patients are also considered for 
radical treatment if they are in a fair general condition, with a CD4 count of more 
than 400 CD4 cells per mm of blood. 
 
The radical approach to treatment at DROUAH entails the combined use of 
chemotherapy and radiotherapy as a modality of treatment. The combined use of 
chemotherapy and radiotherapy is often referred to as chemo-radiotherapy, and 
involves aggressive methods of treatment, often subjecting patients to severe 
adverse effects (Rubatt, Boardman, Segreti, Kavanagh and Wheelock 2007:5). 
These include nausea, vomiting, infection of the urinary tract, metabolic 
derangements, uraemia, haematological and gastro-intestinal toxicities, and skin 
rash (De Vita et al. 2004:887). The radical treatment protocol used at DROUAH 
is outlined in chapter 2 of this research report. 
 
The palliative approach to treatment at DROUAH is determined by the symptoms 
and the extent of the disease in every individual case. The symptoms of 
advanced disease and the extent of progression of the disease vary widely from 
patient to patient (Rubatt et al. 2007:5). The symptoms include vaginal bleeding 
or discharge, localised pain, skeletal pain, fistulas of the bladder or rectum, 
oedema of the lower extremities, deep venous thrombosis, dyspnoea from 
anaemia or pulmonary involvement, uraemia from urethral obstruction and 
 10 
distant metastasis (Rubatt et al. 2007:5). External beam radiotherapy (EBRT), 
using high fraction doses, is widely used in the treatment of advanced disease in 
the Department. 
 
1.9 BACKGROUND TO HIV/AIDS  
 
The Human Immunodeficiency Virus (HIV) attacks the body's immune system 
(Buehler and Ward 1993:118). At first, the immune system fights back by 
producing new T-helper cells, which are better known as CD4 cells (McMichael 
and Dorrell 2005:5).  The virus then multiplies and spreads from one cell to 
another at an incredibly high speed, damaging and destroying cells. HIV 
eventually causes so much damage to the immune system that it fails to keep up 
with the production of new CD4 cells to replace the destroyed cells (Baillieres 
2000:217). When this happens the CD4 cell count drops below 200 cells per mm 
of blood and AIDS develops (Palefsky and Holly 2003:41). Patients in this 
condition are said to be immune suppressed or immune compromised 
(McMichael and Dorrell 2005:5).   
  
Immune compromised patients are vulnerable to infections and other conditions 
that characterise AIDS (Marco 1999:2). Conditions that characterise AIDS are 
referred to as AIDS-defining conditions, and include tuberculosis (TB), 
pneumocystic carini pneumonia, Ca Cx, Kaposi sarcoma, and non-Hodgkin’s 
lymphoma (McMichael and Dorrell 2005:5). 
 
According to the Centres for Disease Control, a CD4 cell count below 200 per 
mm of blood under normal circumstances is a criterion for AIDS (Palefsky  and 
Holly 2003:43). This means that in the absence of AIDS-defining conditions, 
patients with a CD4 cell count below 200 per mm of blood are regarded as 
having AIDS. If patients are diagnosed with any AIDS-defining condition, such 
patients are said to have AIDS, regardless of their CD4 cell count (McMichael 
and Dorrell 2005:5).  
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1.10 INCIDENCE AND PREVALENCE OF HIV/AIDS 
 
Statistics on HIV/AIDS published by the “Until There’s A Cure Foundation” for the 
awareness and prevention of HIV/AIDS, suggest that at the beginning of 2008 
there were 42 million people worldwide living with HIV/AIDS, with over 22 million 
recorded AIDS-related deaths (Kemppainen, Kim-Godwin, Reynolds and 
Spencer 2008:127). The foundation believes that approximately 74% of the 
people diagnosed with HIV/AIDS live in sub-Saharan Africa. The foundation also 
estimates that about 14,000 new infections occur each day, of which more than 
95% occur in poor, developing countries in sub-Saharan Africa and Asia 
(Kemppainen et al. 2008:127). 
 
Walensky and Fofana (2007:1) state that even the best strategic plans would not 
succeed in preventing about one million HIV/AIDS-related deaths in South Africa 
between 2007 and 2010. This prediction is based on projections by the 
Massachusetts General Hospital presented at the HIV Implementers’ Meeting in 
Kigali, Rwanda in 2007. The South African National Strategic Plan on AIDS for 
2008-2011, presents 3 scenarios about the availability of treatment and 
HIV/AIDS-related deaths between 2007 and 2010. The worst-case scenario 
predicts that if there is no growth in the rate of expansion of treatment 
programmes, there will be approximately 2.19 million HIV/AIDS-related deaths in 
South Africa by the end of 2010. The best-case scenario suggests that if 
treatment programmes are expanded so rapidly that 90-100% of those in need 
are reached, there would still be approximately 1.16 million HIV/AIDS-related 
deaths by the end of 2010. The third scenario suggests that if treatment 
programmes are constantly expanded at the required rate, there will be 
approximately 300 000 HIV/AIDS-related deaths in 2010 alone.  
 
1.11 PHYSIOLOGICAL CHANGES CAUSED BY HIV/AIDS  
 
The most significant physiological changes associated with HIV infection relate to 
suppression of the immune system (McMichael and Dorrell 2005:5). Suppression 
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of the immune system results in weakened defences against infections, making 
persons infected with HIV vulnerable to secondary or opportunistic infections and 
other conditions that characterise AIDS (McMichael and Dorrell 2005:6). 
Conditions that characterise AIDS are referred to as AIDS-defining conditions, 
and include tuberculosis (TB), pneumocystic carini pneumonia, Ca Cx, Kaposi 
sarcoma, and non-Hodgkin’s lymphoma (Marco 1999:2). 
 
Gallagher (2007:11) lists chronic fatigue and anaemia as some of the more 
common effects related to the physiological changes caused by HIV infection. 
Baillieres (2000:217) lists anaemia as the most common complication, seen in 
up to 95% of HIV/AIDS patients. Anaemia occurs when the body does not have 
enough blood cells to carry and transport oxygen to various parts of the body 
(Belperio and Rhew 2004:27). All 3 types of blood cells, i.e. red blood cells, 
white blood cells and platelets, are reduced in number in anaemic patients, with 
an increased risk of iron overload (Baillieres 2000:217).  
 
Oxygen is required by the body to produce energy and maintain regular 
metabolism of every organ (Belperio and Rhew 2004:27). A reduction in the red 
blood cell count in particular, decreases the oxygen supply to the tissues in the 
body. Reduced oxygen supplies to the tissues result in a reduction in the body’s 
capacity to produce energy and maintain regular metabolism of the organs 
(Belperio and Rhew 2004:27). This helps to explain why anaemia may result in 
fatigue, loss of energy, general weakness, light-headedness and pallor.  
 
Chronic fatigue is one of the most frequent and distressing symptoms of people 
suffering from HIV-infection (Voss, Dodd, Portillo and Holzemer 2006:38). 
Chronic fatigue is listed as a primary indicator of malfunctions of endocrine 
organs, muscles and the brain, and has been correlated with decreased quality 
of life and functional status (Voss et al. 2006:38).  
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1.12 HIV AND CA CX 
 
In 1993, the United States Centres for Disease Control (CDC) recorded 16 784 
cases of women with AIDS (CDC 1993:11). Among this population of AIDS 
patients, Ca Cx was the most common (1.3%) type of cancer diagnosed (CDC 
1993:11). Subsequently, the CDC added invasive Ca Cx to its list of AIDS-
defining conditions (Clarke and Chetty 2002:19).  
 
Hawes, Critchlow and Niang (2003:557) suggest that women infected with HIV 
have a higher prevalence of infection with HPV, resulting in a higher incidence 
and prevalence of cervical intraepithelial neoplasia (CIN) lesions and a more 
likely rapid progression to invasive Ca Cx. Data published by the Sentinel 
Hospital Surveillance System for HIV infection suggest that the prevalence of 
invasive Ca Cx was higher for HIV-infected women than for uninfected women. 
There were 10.4 cases per 1000 women reported for HIV+ women, and 6.2 
cases per 1000 women reported for HIV- women, representing a relative risk or 
odds ratio (OR) of 1.7; CI 1.1–2.5 (Chin, Sidhu, Janssen and Weber 1998:84). In 
South Africa, the OR of HIV with Ca Cx was found to be 1.6; CI 1.1–2.3 (Sitas, 
Pacella-Norman, Carrara, Patel, Ruff, Sur, Jentsch, Hale, Rowji, Saffer, Connor, 
Bull, Newton and Beral 2000:490). Chirenje (2005:271) states that it is difficult to 
ascertain the actual incidence of Ca Cx in HIV-infected women in HIV-endemic 
countries, where the burden of Ca Cx is the heaviest, but cancer registries are 
still very scanty. 
 
Results based on a study conducted by Abraham and Allegra (2001:219) indicate 
that HIV+ women with Ca Cx have more aggressive and more advanced Ca Cx 
disease than patients who are HIV-. The authors also report that the HIV+ 
patients had a poorer prognosis than those who were HIV-. The authors of the 
study (Abraham and Allegra 2001:221) conclude that there could be a correlation 
between the presence or absence of HIV infection and the responses of patients 
to the same standard of therapy, with the response to therapy expected to be 
worse in HIV+ patients than in HIV- patients.  
 14 
1.13 RATIONALE OF THE STUDY 
 
Oncologists at DROUAH observed that when patients were given the same 
standard of curative or radical chemo-radiotherapy treatment for Ca Cx, the HIV+ 
patients did not tolerate their treatment as well as their HIV-counterparts. The 
oncologists suspected that the HIV+ patients were more prone to the adverse 
effects of the radical chemo-radiotherapy treatment for Ca Cx due to their 
compromised physiological state caused by the HIV infection. This, they thought, 
resulted in the HIV+ patients showing a poorer tolerance of the radical treatment 
than their HIV- counterparts. 
 
The assumptions of the oncologists in the Department seem to be consistent with 
the conclusion drawn by Abraham and Allegra (2001:221). They believe there 
could be a correlation between the presence or absence of HIV infection and the 
responses of patients to the same standard of therapy, with the response to 
therapy expected to be worse in HIV+ patients than in HIV- patients.  
 
The toxic effects of chemo-radiotherapy are expected to induce adverse effects 
in patients who are treated for Ca Cx. Based on the information in the preceding 
sections, it is reasonable to deduce that people with HIV/AIDS have an increased 
predisposition to react negatively to the radical chemo-radiotherapy treatment of 
Ca Cx at DROUAH. In order to test this expectation, it might be useful to address 
the question: What are the responses of HIV positive and HIV negative Ca Cx 
patients, respectively, to radical therapy at the Universitas Annex Hospital? 
 
1.14 AIM AND OBJECTIVES OF THE STUDY 
 
The aim of this study was to analyse the responses of patients who received the 
same standard of radical treatment protocol for FIGO stage II and III Ca Cx at 
DROUAH. The main objective of the study was to determine how the HIV+ 
patients tolerated their treatment. Patients’ treatment tolerance was determined 
by retrospectively analysing their general condition and adverse responses to 
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treatment throughout the treatment schedule and for a period of 18 months after 
conclusion of treatment.  
 
The secondary objective of the study was to retrospectively analyse the overall 
outcomes and therapeutic benefits of the treatment in terms of quality of life and 
tumour responses among the HIV+ patients. The general condition of patients, 
adverse responses to treatment and tumour responses were used to determine 
overall outcomes and therapeutic benefits of the treatment. The HIV- patients 
were included in the study to benchmark the therapeutic benefits in terms of 
quality of life and tumour response.  
 
1.14.1 Adverse responses 
Adverse responses to chemo-radiotherapy are generally accepted as the result 
of dose-related toxicities that patients incur from administration of the chemo-
radiotherapy in the treatment of cancer (Davey, Chaitt, Albert, Piscitelli, Kovacs 
and Walker 1999:851). These toxicities include temporary symptoms that could 
interfere with the activities of the patients’ daily lives (Davey et al. 1999:851). The 
frequency and severity of these responses may vary from patient to patient, and 
from one treatment protocol to another (Grady, Anderson and Chase 1998:230). 
Adverse effects to chemo-radiotherapy may be classified into two groups, namely 
acute and chronic adverse effects (Losso, Belloso, Emery, Benetucci, Cahn and 
Lasala 2000:1616).  
 
According to Losso et al. (2000:1616) the common acute adverse effects 
reported by patients when they receive chemo-radiotherapy for cancers in the 
pelvic area include: diarrhoea; fatigue and tiredness; irritable bladder, commonly 
known as radiation cystitis;  feeling sick, bleeding from the vagina after insertion 
of brachytherapy sources; and pain and redness of the vulva and skin. Losso et 
al. (2000:1616) suggest that it is fairly common for the short-term side-effects to 
continue to get worse for a couple of weeks after the treatment, before they get 
better.  
 
 16 
Long-term adverse effects to chemo-radiotherapy may include reduction or loss 
of function of the bladder and bowel; changes to the vaginal area, such as 
stenosis and fibrosis; early menopause; and infertility (Grady et al. 1998:230). 
The treatment may also have a negative impact on the emotions of patients in 
the long-term. Appendix 2 provides an index with the list and the classification of 
the adverse responses as they were used in this study. 
 
1.15 MOTIVATION AND SIGNIFICANCE OF THE RESEARCH STUDY 
 
The treatment of cancer has always been directed by the principles of maximum 
tumour control and minimum damage to surrounding normal tissue (Bentzen 
2003:77). The overall outcome or efficacy of cancer treatment is measured by 
the extent to which local tumour control and overall and progression-free survival 
are improved, the reduction in side-effects, and the enhancement of quality of life 
(Novetsky, Einstein, Goldberg, Hailpern, Landau, Fields, Mutyala, Kalnicki and 
Garg 2007:637). Medical scientists are always researching new methods and 
exploring technological developments that seek to improve the efficacy of cancer 
treatment (De Vita et al. 2004:7).  
 
The negative impact of HIV/AIDS on the survival rates of cancer patients poses a 
dilemma for the approach of oncologists to the treatment and care of such 
patients. The perception that HIV compromises patients’ response to treatment, 
as well as such patients’ reduced life expectancy, may easily prejudice the way 
oncologists treat these patients.  
 
On the other hand, the advent of more effective highly active anti retroviral 
therapy (HAART) and the availability of other treatment modalities have improved 
survival times for HIV+ patients (Chirenje 2005:276). The treatment and 
management of cancer patients affected by HIV thus demands that oncologists 
remain objective. The objectivity of oncologists is critical in guiding their decisions 
in their choice of the appropriate approach to treatment for the patient and the 
overall therapeutic benefits of such treatment. This study will present objective 
 17 
results regarding HIV+ patients’ tolerance of the radical treatment of Ca Cx at 
DROUAH. The results will help oncologists to confirm or reject their observations 
and/or perceptions about HIV+ patients’ reactions to the radical treatment of Ca 
Cx.  
 
There are two documented studies about patients with Ca Cx at DROUAH. The 
first study was conducted by Friedrich (1996) and the second by Long (2008). 
The focus of Friedrich’s study is a clinical radiobiological analysis of the 
treatment of Ca Cx in Bloemfontein between 1967 and 1990. Long’s study 
analyses the effectiveness of dose and the incidence of late rectal complications 
where high dose-rate brachytherapy was used in the treatment of FIGO stage I – 
III Ca Cx. This study is unique in the sense that it analyses the way in which a 
specific group of (HIV+) patients tolerated their treatment. The results of the 
current study will guide oncologists in making objective judgements about the 
efficacy of radical cancer treatment and its impact on patients’ quality of life.  
 
1.16 STRUCTURE OF THE DISSERTATION 
 
Chapter 1:  Introduction and Background  
Chapter 1 constitutes the introduction to the study and provides background 
information on Ca Cx and the treatment and management of the disease. HIV 
and its possible role in and influence on the treatment and management of Ca 
Cx, as well as its relevance to the study, are also discussed. The chapter 
concludes with the rationale, aims and objectives of the study, as well as the 
motivation for and significance of the study. 
 
Chapter 2:  Literature Review 
The literature review presents information on the application of chemo-
radiotherapy in the treatment and management of FIGO stage II and III (invasive) 
Ca Cx. The uses of external beam radiotherapy (EBRT), intra-cavitary 
brachytherapy (ICBT) and chemotherapy in the treatment of Ca Cx, with Cisplatin 
as a chemotherapeutic agent, are also investigated. The chapter looks at the 
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radical approach to the treatment of Ca Cx in the Department, as well as cases 
from the applicable literature. 
 
Chapter 3: Materials and Methodology 
In chapter 3, a description is given of the selection of patients for the study, the 
research tools, the methods and materials used during the study, and the way in 
which data was collected and analysed. A brief account is also given of the 
procedures that were used to acquire the necessary consent to conduct the 
study and to access information and data from patient files. In complying with the 
proposal of the research study, a pilot study was conducted. Information on the 
pilot study is also provided in this chapter.  
 
Chapter 4: Results  
Chapter 4 presents the results of the study. The chapter also provides 
information on patient inclusion procedures, analysis of the patients’ clinical 
information and status at referral for treatment in the Department, as well as 
analysis of the responses of each group of patients with regard to specific 
variables at specific intervals.  
 
Chapter 5: Discussion and Conclusion  
This chapter discusses the responses of FIGO stage II and III Ca Cx patients to 
the radical treatment protocol at DROUAH. The HIV+ patients’ tolerance of the 
radical treatment, the overall outcomes and the therapeutic benefits of the 
treatment are also discussed. The challenges and shortcomings of the study, as 
well as recommendations, are also shared.  
 
1.17 CONCLUSION 
 
The approach to the treatment and management of patients with a dual diagnosis 
of Ca Cx and HIV/AIDS can be easily influenced by the attitudes and perceptions 
outlined in section 1.1, relating to fear and hopelessness. The treatment and 
management of patients require healthcare practitioners to be objective and 
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balanced at all times, with regard to their judgement and the treatment options 
they offer their patients. Despite the possible risks posed by the impact and 
implications of the dual diagnosis of Ca Cx and HIV/AIDS, the objective and 
balanced judgement of healthcare practitioners and the treatment options that 
they offer their patients should not be influenced by these possible risks. Until 
there is factual proof that HIV+ patients with Ca Cx tolerate their treatment less 
well than their HIV- counterparts, the approach to patients’ treatment should be 
based on the premise that the treatment responses and tolerance levels are the 
same in HIV- and HIV+ patients treated for the same standard of therapy. The 
current study aims to shed more light on HIV+ patients’ tolerance of treatment. 
Chapter 2 outlines the literature review conducted for the purposes of the current 
study. 
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2. CHAPTER 2: LITERATURE REVIEW 
 
2.1 INTRODUCTION 
 
Radiotherapy and chemotherapy are both widely used in the management of 
gynaecological malignancy (Symonds and Foweraker 2006:100). Thomas 
(1999:1198) suggests that several clinical trials have demonstrated the value of 
adding chemotherapy to radiotherapy to decrease mortality rates from cancer. 
However, the toxicity of chemotherapeutic agents is always a primary concern 
when used in the treatment of cancer (Thomas 1999:1198).  
 
The current study was motivated by the nagging suspicion of oncologists that 
HIV+ patients do not tolerate the chemo-radiotherapy treatment for Ca Cx at 
DROUAH as well as their HIV- counterparts. This belief was based on 
observations in the clinical setting. The current study aims to test the validity of 
this feeling among oncologists.  
 
This literature review investigates the use of chemo-radiotherapy as a modality 
for the treatment and management of FIGO stage II and III (invasive) Ca Cx. The 
literature review offers some background information on EBRT, ICBT and 
chemotherapy, and their use in the treatment and management of Ca Cx. 
Cisplatin is discussed as a chemotherapeutic agent. The chapter provides 
information on the radical approach to the treatment of Ca Cx at DROUAH. The 
literature review also looks at other approaches to the treatment of stage II and III 
Ca Cx, obtained from the studies consulted for this project. 
 
The findings collected in the literature served as a benchmark for the findings of 
this study. The next section outlines the approach and methods that were used to 
access relevant studies.  
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2.2 SEARCH STRATEGY AND CRITERIA 
 
The literature review process entailed the exploration of publications such as 
books and journals, as well as the investigation of Internet resources. Especially 
helpful were publications that focused on the treatment of stage II and III Ca Cx 
where chemo-radiotherapy was used, or studies that involved stage II and III Ca 
Cx patients that were HIV+. Studies about chemo-radiotherapy included those 
referring to the use of EBRT or high-dose (HDR) ICBT. EBRT and HDR-ICBT 
were used either in combination or separately. During the literature review care 
was taken to include studies published during the past two decades (i.e. from the 
1980s to the present time) in order to get a perspective on the advances and 
developments in the treatment and management of Ca Cx, FIGO stage II and III, 
especially in the areas of chemo-radiotherapy and HIV/AIDS.  
 
For Internet searches, keywords were used to search the Science Direct, 
PubMed/MEDLINE, Ebsco and Google search engines. Keywords included, inter 
alia, the following: concurrent chemotherapy and radiotherapy for Ca Cx; chemo-
radiotherapy in carcinoma of the uterine cervix; impact of HIV/AIDS on Ca Cx; 
toxicity of cancer treatment; and trends in Ca Cx treatment. The website of the 
Central University of Technology, Free State, South Africa (www.cut.ac.za) also 
provided valuable links through the EbscoHost, SpringerLink and ISI Web of 
Science links. The website of the National Cancer Institute of the United States of 
America, better known as the NCI, was also accessed for announcements, press 
releases and information about publications relevant to this study. Only English 
books and publications were considered for the literature review. 
 
The findings in the literature will be used to compare the benefits of the radical 
chemo-radiotherapy treatment approach at DROUAH with the adverse effects of 
the approach, particularly on HIV+ patients. The next section gives a description 
of radiotherapy and its uses in the treatment and management of Ca Cx, FIGO 
stage II and III.  
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2.3 RADIOTHERAPY FOR STAGE II AND III CA CX 
 
Radiation therapy, commonly referred to as radiotherapy, plays an important role 
in the treatment of Ca Cx, and has proven to be a very effective mode of therapy 
for the treatment of stage II and III Ca Cx (Graham, Sotto and Paoloucek 
1988:56). Radiotherapy can be employed alone, or in combination with other 
therapies, such as chemotherapy and, in rare cases, surgery (De Vita et al. 
2004:277). Radiotherapy for Ca Cx is available in two modalities, namely 
external beam radiation therapy (EBRT) and intracavitary brachytherapy (ICBT). 
EBRT uses an external source of radiation whilst ICBT refers to a source that is 
implanted in the relevant anatomical area.  
 
The choice of radiotherapy modality in the treatment of Ca Cx is influenced by 
factors such as efficacy, availability of equipment, duration of treatment, 
expertise, and safety considerations (Nag, Dally, De la Torre, Tatsuzaki, 
Kizilbash, Kurusun, Pinilos, Pokrajac, Sur and Levin 2002:298). The choice 
between the use of EBRT and ICBT in combination or as separate modalities is 
determined by the availability of these modalities in the treatment facility (Nag et 
al. 2002:298).  
 
The curative potential of radiotherapy in the treatment of Ca Cx is enhanced by 
using ICBT. This means that EBRT is used as the primary treatment source to 
spread the radiation dose throughout the treatment volume, while ICBT is given 
to supplement or “boost” the EBRT dose. (Patel, Rai, Malick and Sharma 
2005:125). Thomas (2000:46) suggests that the standard approach to 
radiotherapy for any Ca Cx that has advanced beyond FIGO stage I should be 
the use of EBRT in combination with ICBT. This has an added impact on the 
tumour, while sparing the normal surrounding tissues.  
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2.3.1 External beam radiotherapy (EBRT) for stage II and III Ca Cx 
The American Brachytherapy Society (ABS) acknowledges that the EBRT dose 
given to the whole pelvis varies from one institution to another, with the fraction 
sizes being determined by the envisaged total EBRT dose and overall treatment 
time (Nag, Erickson, Thomadsen, Orton, Demanes and Petereit 2000:203). 
Some institutions give a limited dose to the whole pelvis in patients with early 
stage disease, with the first fraction of ICBT being given after an EBRT dose of 
20 Gy to the whole pelvis. In such cases, the ABS recommends that the size and 
number of ICBT fractions should be increased, whilst care is taken that individual 
fraction sizes are kept below 7.5 Gy to keep rectal dose levels in check.  
 
DROUAH uses a total EBRT dose of 50 Gy, using daily fractions of 2 Gy. This 
dosage is in line with those of other centres across the world, where EBRT doses 
to the whole pelvis range from 40 – 50 Gy, with doses varying between 1.5 Gy to 
2 Gy per fraction. Unlike the case where EBRT doses of 20 Gy are given to the 
whole pelvis, with 7.5 Gy ICBT fractions, centres using the 40 – 50 Gy whole 
pelvis EBRT dose approach, including DROUAH, should use smaller ICBT 
fractions – about 2 – 2.5 Gy (Nag et al. 2000:203). 
 
2.3.2 Intracavitary brachytherapy (ICBT) for stage II and III Ca Cx 
There are two approaches to the use of ICBT in the treatment of Ca Cx. One 
approach is to use low-dose-rate ICBT (LDR-ICBT), and the other is to use high-
dose-rate ICBT (HDR-ICBT). LDR is defined as a dose of 0.4 – 2 Gray per hour 
(Gy/h), and HDR is defined as a dose of more than 12 Gy/h (International 
Commission on Radiation Units and Measurements (ICRU) 1985). LDR-ICBT 
has been in use for the treatment of Ca Cx for more than a century, and has 
undergone continuous refinement during this period (Ferrigno, Nishimoto, Dos 
Santos-Novaes, Pellizzon, Maia, Fogarolli and Salvajoli 2005:1108). HDR-ICBT 
for Ca Cx has been in use for over 30 years, and is widely applied throughout 
Asia and Europe, and its use is steadily increasing in North and South America 
(Nag, Orton and Young 1999:111).  
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The Patterns of Care Studies show that, in the United States, the use of HDR for 
the treatment of Ca Cx increased from 9% during 1992–1994 to 16% during 
1996–1999, although this increase did not reach significance (Eifel, Moughan, 
Erickson, Larocci, Grant and Owen 2004:1145). LDR techniques were developed 
in an era when remote afterloading technology was unavailable. Remote 
afterloading techniques were developed due to concerns about health care 
workers’ exposure to radiation.  
 
The use of HDR-ICBT is the result of technological development in the 
manufacturing of high-intensity radioactive sources, sophisticated computerised 
remote afterloading devices and treatment planning software (Martinez, Stitt and 
Speiser 1997:569). Some advantages of HDR-ICBT include the following: shorter 
treatment times; the prospect of improved immobilisation; patients can receive 
their treatment on an outpatient basis; accuracy of the source and applicator 
positioning; and individualised treatment with source optimisation. These 
advantages offer the benefit of reduced hospitalisation costs, less disruption in 
patients’ daily routines, reduced risk of applicator movement during treatment, 
higher rate of patient throughput in busy departments and improved radiation 
protection for personnel and the general public (Wright, Jones and Whelan 
1994:188).  
 
Sarkaria, Petereit, Stitt, Hartman, Chappell, Thomadsen, Buchler, Fowler and 
Kinsella (1994:75) reported on a study they conducted to compare the efficacy 
and complication rates of LDR-ICBT versus HDR-ICBT in the treatment of FIGO 
stage IB to IIIB Ca Cx, with curative intent. A combination of EBRT and LDR-
ICBT was used for one group, and a combination of EBRT and HDR-ICBT was 
used for another group. Sarkaria et al. (1994:79) observed that the treatment 
results for LDR-ICBT and HDR-ICBT were similar with respect to survival rates, 
pelvic control and late complications in the treatment of Ca Cx. They concluded 
that HDR brachytherapy appears to be a safe and effective alternative to LDR 
therapy in the treatment of Ca Cx. The effectiveness of treatment relates to local 
tumour control and the incidence of radiation effects. However, the authors 
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(Sakaria et al. 1994:80) mention that HDR-ICBT has more advantages, such as 
improved convenience for patients and less exposure to radiation for healthcare 
workers. 
 
Ferrigno et al. (2005:1115) applied a retrospective analysis to gain insight into 
the comparative outcome of FIGO stage I to III Ca Cx patients treated with LDR-
ICBT and HDR-ICBT, respectively. The authors concluded that there were similar 
outcomes for LDR-ICBT and HDR-ICBT in the treatment of FIGO stages I and II. 
In FIGO stage III, lower overall and disease-free survival rates and marginally 
lower local control were observed when HDR-ICBT was used. Fewer late rectal 
complications were also observed in the patients who received HDR-ICBT. The 
authors attribute these findings to the relatively low dose of HDR-ICBT delivered 
at Point A. Point A is defined as a geometric point in relation to the cervical os 
and the uterine axis (Perez 1998:1751). The rectal dose and the total number of 
fractions given are influenced by the anatomical layout in the surrounding area 
(Perez 1998:1751). HDR-ICBT has the potential of improving the optimisation of 
dose distribution (Nag 2004:620). Optimisation of dose distribution is useful in 
addressing the challenges presented by rectal tolerance doses in brachytherapy 
(Nag 2004:620). 
 
Technical advances in HDR-ICBT and its advantages over LDR-ICBT has made 
this modality of radiotherapy, in combination with EBRT, a key role-player in the 
treatment and management of invasive Ca Cx (Nag et al. 2002:299). The high 
incidence of Ca Cx in developing countries is the most common justification for 
the choice of HDR-ICBT for gynaecological cancers (Nag et al. 2002:299). The 
justification for the choice of HDR-ICBT for gynaecological cancers, as 
postulated by Nag and co-workers, is accordingly also applicable in the South 
African context. 
 
The use of HDR-ICBT in the treatment of Ca Cx is relevant to the current study 
because HDR-ICBT is used as a modality of radiotherapy in the radical treatment 
of invasive Ca Cx at DROUAH. HDR-ICBT is used to “boost” EBRT, which is 
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given as the primary course of radiotherapy. Chemotherapy and its uses in the 
treatment and management of Ca Cx, FIGO stage II and III are discussed next.  
 
2.4 CHEMOTHERAPY FOR STAGE II AND III CA CX 
 
Chemotherapeutic agents currently in use are cytotoxic radiosensitisers that 
affect both normal and malignant cells (Steel 2002:224). Practically all patients 
who are in good medical condition and receiving radiation for invasive Ca Cx are 
offered chemotherapy in addition to their radiation (Perez 1998:1760). It may 
even be offered for earlier stage patients, at the discretion of the oncologists. 
Chemotherapy is not known to be very effective when used alone as a primary 
treatment modality (Thomas 1999:1199).  
 
Several clinical trials have demonstrated the usefulness of adding chemotherapy 
to radiation in terms of decreasing mortality rates from Ca Cx (Thomas 
1999:1199). Evidence suggests that giving chemotherapy and radiotherapy 
together improves overall survival in patients treated for invasive Ca Cx (Green, 
Kirwan, Tierney, Symonds, Fresco, Collingwood and Williams 2001:782). There 
is also evidence that combined chemo-radiotherapy delays tumour recurrence 
and reduces the risk of recurrence and distant metastasis. An increase in side-
effects has been noted when chemotherapy is used in the treatment of invasive 
Ca Cx. Haematological and gastro-intestinal toxicities are among the most 
common side-effects of chemotherapy (Green et al. 2001:782). 
 
Various chemotherapeutic agents are available, and they are often given in 
combinations for a series of months (Steel 2002:224). The chemotherapy 
regimen given to patients is normally at the discretion of the oncologists, and this 
is influenced by various factors, such as financial considerations, availability, 
politics and even personal preference (Thomas 1999:1199). Cisplatin is among 
the most commonly used chemotherapeutic agents (Green et al. 2001:781). 
Cisplatin is of interest to the current study since it is the chemotherapeutic agent 
that forms part of the chemo-radiotherapy protocol for patients treated for Ca Cx 
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with radical intent at DROUAH. The radical chemo-radiotherapy protocol for Ca 
Cx forms part of this study. The next section discusses Cisplatin as a 
chemotherapeutic agent. 
 
2.4.1 Cisplatin as a chemotherapeutic agent 
Cisplatin is a chemotherapeutic agent and is classified as an alkylating drug in 
terms of the American Chemical Abstract Registry (Bentzen 2003:81). Cisplatin 
is a platinum-based radiosensitiser with cytotoxic characteristics that affect 
normal and malignant cells, and was the first medicine developed in that drug 
class (Peters, Liu, Barrett, Stock, Monk, Berek, Souhami, Grigsby, Gordon and 
Alberts 2000:1613). Ca Cx and various other cancers, including testicular, 
ovarian, bladder, head and neck, oesophageal, small and non-small cell lung, 
breast, cervical and stomach cancers can be successfully treated with Cisplatin 
(Bentzen 2003:81).  
 
Like other chemotherapeutic agents, Cisplatin induces side-effects when used in 
the treatment of Ca Cx (Perez 1998:1760). However, Cisplatin does offer several 
benefits that have proven to outweigh the side-effects that it may cause (Classe, 
Morice and Rodier 2002:61). The side-effects of Cisplatin and their severity 
depend on the dosage that is administered, with higher doses more likely to 
produce more severe side-effects. The presence or severity of side-effects of 
Cisplatin has no known relationship with the efficacy of the drug. Despite the 
possible gains in overall survival ratios when Cisplatin is combined with 
radiotherapy in the treatment of Ca Cx, the acute adverse effects of treatment 
can be aggravated by the side-effects of Cisplatin (McArdle and Kigula-Mugambe 
2007:96). 
 
Some common side-effects of Cisplatin, occurring in more than 30% of patients 
who receive the drug, are nausea and vomiting, kidney toxicity and abnormalities 
in blood tests (Thomas 1999:1199). Kidney toxicity includes nephritis and 
nephrotoxicity, and can lead to elevations in serum creatinine levels. 
Abnormalities in blood tests include decreased magnesium, calcium and 
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potassium levels, low white blood counts and low red blood cell counts 
(anaemia). Low white blood cell counts can increase the risk of infections in 
patients. Cisplatin may be inadvisable for patients who have a history of severe 
allergic reaction to platinum-containing formulations, and is not recommended for 
patients receiving any kind of immunisation or vaccination (Peters et al. 
2000:1613). 
 
The overall outcome or efficacy of cancer treatment is measured by the extent to 
which local tumour control and overall and progression-free survival rates are 
improved, the reduction in side-effects and the enhancement of quality of life 
(Novetsky et al. 2007:637). Medical scientists are always trying to improve the 
efficacy of cancer treatment through research and technological development 
(De Vita et al. 2004:7).  
 
The aforementioned information on the characteristics, uses and effects of 
radiotherapy and chemotherapy in the treatment of Ca Cx, as well as the side-
effects of Cisplatin as a chemotherapeutic agent, are critical factors in 
understanding the relevance of this study. In order to contextualise this 
information, the radical approach to the treatment and management of FIGO 
stage II and III Ca Cx at DROUAH is described next. 
 
2.5 TREATMENT FOR STAGE II AND III CA CX AT UNIVERSITAS 
ANNEXE HOSPITAL 
 
The treatment approach for Ca Cx, FIGO stage II and III at DROUAH involves 
radical chemo-radiotherapy. To be considered for the radical treatment protocol, 
patients are required to be in a good or fair general condition in the opinion of the 
oncologists upon referral for treatment. Patients are classified in accordance with 
the index provided in appendix 2. HIV- and HIV+ patients are considered for 
inclusion in the radical treatment protocol. If patients are HIV+, they need to have 
a CD4 count of more than 200 CD4 cells per mm of blood, and they need to be in 
a good general condition. However, HIV+ patients are also considered for radical 
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treatment if they are in a fair general condition with a CD4 count of more than 
400 CD4 cells per mm of blood. 
 
The radical chemo-radiotherapy protocol consists of a combination of EBRT, 
HDR-ICBT and weekly cycles of chemotherapy given concurrently. EBRT in this 
protocol involves administering a total dose of 50 Gy in daily fractions of 2 Gy (2 
Gy / fraction), for a total of 25 fractions. The HDR-ICBT is administered weekly, 
using the Nucletron Microselectron® (1994) Afterloading unit. The Microselectron 
Afterloading unit is loaded with an Ir-192 source, using a central uterine applicator 
and a ring applicator. The first HDR-ICBT fraction is administered in the third 
week of the treatment schedule, with consecutive weekly fractions in the 
subsequent weeks of treatment. The HDR-ICBT is given on days when patients 
do not receive EBRT. The weekly dosage varies between 2.0 Gy and 2.5 Gy per 
fraction, given in 4-6 fractions. The HDR-ICBT is normalised to the highest 
rectum dose point, to achieve a minimum total dose of 15 Gy to point A.  
 
Cisplatin is given concurrently as the preferred chemotherapeutic agent. The 
Cisplatin is administered weekly, using doses of 25 mg/m2 per week for 5 weeks 
(5 cycles). The chemotherapy is given on days when patients do not receive 
HDR-ICBT. The total time required for the administration of the radical treatment 
protocol, or rather, the overall treatment time (OTT), extends over a period of 
approximately 7 weeks. Throughout the treatment schedule, the patients have to 
undergo prescribed clinical care and management procedures. These 
procedures are outlined in the next section. 
 
2.5.1 Clinical care and management of patients during treatment in the 
department 
Oncologists have weekly routine consultations with patients who are on the 
treatment protocol in the Department. In this way, patients are monitored and 
provided with whatever clinical or medical support or interventions they might 
need. Monitoring involves examining the patients and analysing available clinical 
reports and data. Reports of adverse responses to treatment are also recorded 
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and treated appropriately. Adverse effects range from minor to severe responses 
to treatment. Adverse responses are classified and recorded in accordance with 
the index contained in appendix 2.  
 
Blood samples for haematology studies are drawn on a weekly basis. 
Haematology studies provide oncologists with additional information on a 
patient’s general condition and the effects of treatment on the patient. 
Haematological tests monitor, among other things, the levels of haemoglobin, 
leucocytes, platelets, urea and electrolytes (U+E), and creatinine. Chemo-
radiotherapy has potentially toxic effects, which place a huge strain on the body’s 
energy resources (De Vita et al. 2004:887). Monitoring the blood levels of 
patients who are receiving chemo-radiotherapy helps physicians to predict the 
ability of patients to endure the vigorous demands and possible adverse effects 
of the treatment they receive (De Vita et al. 2004:887).  
 
Haemoglobin levels give an indication of the blood-oxygen levels, which relate to 
the enhancement of the radiobiological effects of radiation therapy (Steel 
2002:225). Testing for leukocytes gives a good indication of the body’s ability to 
fight or overcome any disease or infection. Patients are considered for 
chemotherapy if they have a minimum leukocyte count of 1500/mm3. Platelets, 
on the other hand, are useful in helping the blood to clot, especially when there is 
a possibility of uncontrolled bleeding in the body.  
 
U+E is a measure of kidney function, which is important in maintaining the 
electrolyte balance of the body (Steel 2002:225). This is particularly important in 
cases where dehydration or toxicity may occur. Creatinine is a molecule of major 
importance for energy production in muscles and a good indicator of kidney 
function. Abnormally high levels of creatinine thus warn of possible malfunction 
or failure of the kidneys, sometimes even before a patient reports any symptoms. 
 
The aim of the current study was to determine how HIV+ patients tolerated their 
chemo-radiotherapy regimen and to analyse the overall outcomes and 
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therapeutic benefits of the treatment. General condition of patients, adverse 
responses to treatment and tumour responses were the variables used as a 
yardstick to determine overall outcomes and therapeutic benefits. An exploration 
of the relevant literature was chosen as the most appropriate tool to acquire data 
on the experiences and evidence from other treatment centres, using similar or 
related treatment techniques. Applicable evidence and experiences related to 
chemo-radiotherapy regimens are presented in the next section. 
 
2.6 CHEMO-RADIOTHERAPY FOR STAGE II AND III CA CX 
 
The current study focused on the responses of HIV+ and HIV- patients treated for 
Ca Cx with chemo-radiotherapy with radical intent, in order to determine how 
HIV+ patients tolerated their treatment. Chang et al. (2006:879) assert that 
chemo-radiotherapy, using a combination of EBRT and ICBT, is the treatment of 
choice for FIGO stage II to IVA invasive Ca Cx. The assertions of Chang et al. 
(2006:879) are supported by the results of a retrospective analysis conducted by 
Ferrigno, Dos Santos-Novaes, Pellizzon, Maia, Fogarolli, Gentil and Salvajoli 
(2001:1123) 
 
The analysis conducted by Ferrigno et al. (2001:1123) is based on dose 
effectiveness and late radiation complications in 138 patients with Ca Cx, FIGO 
stages II and III. The patients were given 25 fractions of EBRT, which amounted 
to a total dose of 45 Gy to the whole pelvis. HDR-ICBT was given in four weekly 
fractions of 6 Gy to point A, which amounted to a total of 24 Gy. The results 
suggest overall survival, disease-free survival and local control rates of 53.7%, 
52.7%, and 62% at 5 years, respectively. The incidence of rectal, bladder and 
small bowel late complications was 16%, 11% and 14%, respectively. Although 
this is an analysis of late complications, the results do offer insight into the long-
term effectiveness of the treatment approach in terms of improved prospects of 
survival and limited late treatment complications.  
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Green et al. (2001:783) published the findings of their multi-centre trials 
conducted on patients treated for Ca Cx, FIGO stage IB to IVA. The trials 
involved 4580 randomised patients treated at six centres in the United Kingdom 
between 1981 and 2000. The results from these trials indicate that the overall 
survival rate of patients on chemo-radiotherapy regimens improved by 12%. 
These improved survival rates were observed even in cases where agents other 
than Cisplatin were used. Progression-free survival among patients on the 
chemo-radiotherapy regimens improved by 16% (Green et al. 2001:783).  
 
Green et al. (2001:783) ascribe significant benefits concerning local and distant 
recurrence to the use of chemo-radiotherapy. Odds ratios of 0.61, p<0·0001, and 
0.57, p<0·0001, were recorded for local recurrence and distant metastasis, 
respectively. The authors believe that concomitant chemo-radiotherapy appears 
to improve overall and progression-free survival rates and reduces local and 
distant recurrence in patients with Ca Cx. The authors suggest that such 
concomitant chemotherapy may afford the radiosensitisation and systemic 
cytotoxic effects (Green et al. 2001:783). 
 
Despite the gains in overall and progression-free survival rates, and the reduced 
probability of local recurrence and distant metastasis, there was evidence of an 
increase in side-effects when chemotherapy was used in combination with 
radiotherapy. Most of the recorded side-effects were related to haematological 
and gastrointestinal toxicities. Even though chemotherapeutic agents other than 
Cisplatin were used in the trials reported by Green et al. (2001:783), the 
occurrence of haematological and gastrointestinal toxicities seems to correlate 
with the side-effects of Cisplatin described in section 2.4 above.  
 
Morris and associates reported their findings of studies conducted in Texas, 
between 1990 and 1997 (Chang et al. 2006:881). These studies included 403 
women with Ca Cx, FIGO stages IIB to IVA. The study compared the effect of 
radiotherapy (EBRT combined with ICBT) with the effect of chemo-radiotherapy. 
In the chemo-radiotherapy approach, Cisplatin was used as the 
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chemotherapeutic agent. Morris and associates reported that even though a 
larger number of rectal complications were observed in the chemo-radiotherapy 
group, the treatment yielded improved local tumour control and overall disease-
free survival rates (Chang et al. 2006:885). 
 
Toita, Moromizato, Ogawa, Kakinohana, Maehama, Kanazawa and Murayama 
(2005:665) conducted a retrospective study on 52 patients to assess the 
feasibility and efficacy of concurrent chemo-radiotherapy in the treatment of 
patients with invasive Ca Cx, FIGO stage IB-IVA. All patients were treated with a 
combination of EBRT and HDR-ICBT, using Ir-192. Cisplatin was used as the 
chemotherapeutic agent in the treatment protocol. The results indicate that the 
actuarial 3-year pelvic control rate, disease-free survival rate and overall survival 
rate were 91%, 67% and 79%, respectively. Acute toxicity was also reported in 
most patients, with haematological toxicity being the most prevalent, with 83% of 
patients showing effects in their leukocyte counts. Other forms of acute toxicity 
reported were nausea and vomiting (28%), and diarrhoea (15%). Thirty-two 
percent (32%) suffered late radiation complications. One (1) patient suffered 
enterocolitis, while seven patients incurred pelvic infection that required 
treatment.  
 
Toita et al. (2005:670) is of the opinion that concurrent chemo-radiotherapy with 
HDR-ICBT is feasible and efficacious for patients with Ca Cx. The authors further 
state that despite the limited number of patients and limited follow-up period, the 
retrospective study demonstrated a high rate of pelvic control and survival, with 
an acceptable level of acute and late toxicities for patients with loco-regionally 
advanced Ca Cx. The reports by Toita and associates do not provide specifics 
about dosage and fractionation schedules, and the nature and extent of late 
radiation complications. However, the use of EBRT, Ir-192 HDR-ICBT and 
Cisplatin as treatment modalities for invasive Ca Cx makes their results and 
observations relevant to the current study. 
 
The South Koreans Lee, Wu, Kim, Ha, Kim, Kim and Lee (2007:95) conducted a 
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study involving 33 patients who were treated between March 2000 and January 
2004 to evaluate the toxicity and efficacy of chemo-radiotherapy as a definitive 
treatment for FIGO stage IB to IVB squamous Ca Cx. The patients were treated 
with concurrent chemo-radiotherapy, using EBRT and ICBT, with a 
chemotherapy combination of Paclitaxel and Carboplatin given concurrently. Lee 
et al. (2007:98) report that there were three interruptions in patients’ treatment 
secondary to toxicity. The toxicities were graded according to the NCI Common 
Toxicity Criteria (2006, v. 3.0). All three of these patients developed grade 4 
neutropenia. Chemo-radiotherapy was delayed a week for two patients, and the 
second cycle of chemotherapy was delayed three weeks for one patient.  
 
Lee et al. (2007:98) also report that patients incurred haematological toxicity, with 
leucopenia being the most common form of this type of toxicity. Grade 3 
leucopenia was observed in 17 patients, representing 52% of the study 
population, while three patients (9%) incurred grade 4 leucopenia. Grade 3 
nausea was observed in one patient. Vesicovaginal fistulas occurred in two 
patients (6%) as a late complication. Seventy percent (70%) of patients showed a 
complete response (CR) and 30% showed a partial response (PR) for Ca Cx. 
The authors claim that the overall survival rate in this study was superior to that 
of the historical control group of their institute, in which all patients were treated 
with radiotherapy alone. The authors conclude that this regimen was tolerated 
well and showed excellent local control rates. 
 
The literature consulted for this study suggests that concurrent chemo-
radiotherapy regimens can be accepted as an effective approach to the 
treatment and management of Ca Cx. Based on data from five randomised trials, 
the National Cancer Institute (NCI) released a consensus statement in February 
1999, declaring that concurrent chemo-radiotherapy should be considered as the 
new standard of care for all patients with Ca Cx (Kim, Cho, Keum, Lee, Seong, 
Suh and Kim 2007:58). Evidence collected from the literature consulted for this 
study and discussed in preceding sections underscores the importance of the 
NCI campaign. The support for the use of chemo-radiotherapy as the treatment 
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of choice for FIGO stage II and III Ca Cx is based on the effectiveness of these 
treatment modalities in terms of local tumour control, overall and progression-free 
survival, incidence of side-effects and quality of life (Ferrigno et al. 2001:1132). 
The effectiveness of treatment in improving local tumour control, increasing 
overall and progression-free survival and enhancing quality of life seems to 
outweigh the adverse effects incurred from the treatment given (Ferrigno et al. 
2001:1132). 
 
The prevalence of HIV/AIDS among patients reporting for treatment of Ca Cx at 
DROUAH poses the challenge of influencing the outcome of treatment. The 
potential challenges arise from the physiological changes caused by HIV/AIDS, 
such as anaemia and chronic fatigue (Gallagher 2007:11). Fatigue is associated 
with decreased quality of life and functional status (Voss et al. 2006:38).   
 
Other potential challenges arise from evidence that suggests the following: HIV+ 
women have more aggressive and more advanced Ca Cx disease than HIV- 
patients; HIV+ patients with Ca Cx have a poorer prognosis than their HIV- 
counterparts; and there seems to be a correlation between the presence or 
absence of HIV and the responses of patients to the same standard of therapy, 
with the HIV+ patients expected to do worse than the HIV- patients (Abraham 
and Allegra 2001:222). The next section offers brief background information on 
chemo-radiotherapy approaches to the treatment of invasive Ca Cx in HIV+ 
patients. 
 
2.7 CHEMO-RADIOTHERAPY TREATMENT OF CA CX IN HIV+ PATIENTS  
 
The treatment of invasive Ca Cx in HIV-positive women depends on local 
guidelines and the availability of resources (Chirenje 2005:6). HIV-infected 
women are observed to present with disease at a more advanced stage than 
HIV-negative women, particularly when their CD4 cell counts are below 200/mm3 
(Fruchter, Maiman, Arrastia, Matthews, Gates and Holcomb 1998:244). 
Treatment outcomes for invasive Ca Cx are observed to be poorer in HIV+ 
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women than in HIV-negative women, with recurrence rates of up to 88%, as 
observed in a study of HIV-infected women with Ca Cx in New York City 
(Maiman, Fruchter, Clark, Arrastia, Matthews and Gates 1997:79).  
 
McArdie and Kigula-Mugambe (2007:94) conducted an important prospective 
study in Uganda. The study assessed the eligibility of patients living in the 
developing world and suffering from Ca Cx for concomitant chemo-radiotherapy. 
The chemo-radiotherapy protocol involved the use of EBRT and ICBT, with 
concomitant Cisplatin administered weekly. The study by McArdie and Kigula-
Mugambe (2007:94) was based on concerns that the highest incidence of Ca Cx 
occurs among women in the developing world, who are faced with multiple 
challenges. These challenges include economic, social and geographical factors, 
which are further exacerbated by co-existing HIV and poor nutritional status 
(McArdie and Kigula-Mugambe 2007:94).  
 
The study by McArdie and Kigula-Mugambe (2007:96) was based on a sample 
size of 314 patients (n = 314), with histologically confirmed FIGO stage II and III 
Ca Cx. Fifty percent (50%) of the patients in the study were HIV+, whilst 11.6% of 
the patients were confirmed to be HIV+. HIV status was not confirmed in 38.4% 
of the patients. The results indicated that of the 314 patients who were referred 
for chemo-radiotherapy treatment, 47 patients (15.1%) were eligible for combined 
modality treatment and 190 (60.5%) were not eligible on the basis of the 
exclusion criteria for the study. Eligibility could not be established in 77 cases 
(24.4%). McArdie and Kigula-Mugambe (2007:96) state that patients were 
excluded from the chemo-radiotherapy treatment in the following cases: FIGO 
stage IA and IV; haemoglobin (Hb) count of less than 8 g/dL; leucocyte count of 
less than 2000/µL; platelet count of less than 100,000/µL; and creatinine count of 
more than 97 µmol/L.  
 
Based on their results, McArdie and Kigula-Mugambe (2007:97) conclude that a 
small proportion of patients with Ca Cx are likely to benefit from the chemo-
radiotherapy treatment using concomitant weekly Cisplatin. These results concur 
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with the findings of Green, Kirwan, Tierney, Vale, Symonds, Fresco, Williams and 
Collingwood (2005:25), and the results published by Lukka, Hirte, Fyles, 
Thomas, Elit, Johnston, Fung and Browman (2002:210). The results from the two 
aforementioned studies suggest that the contribution of concomitant chemo-
radiotherapy to overall survival advantage in the treatment of Ca Cx ranges 
between 10% and 16%. Even though overall survival rate is not the focus of the 
current study, the information obtained from the aforementioned studies throws 
more light on the assessment of the therapeutic benefits of the chemo-
radiotherapy protocol for HIV+ patients.  
 
Treatment options for invasive Ca Cx in HIV+ patients are determined by the 
stage of the Ca Cx, as well as careful assessment of the general medical 
condition of each patient (Chirenje 2005:6). Radical radiotherapy is useful for 
large lesions (FIGO stages IB2, and stages IIB–IVA), those who are medically 
unfit for surgery, and situations where surgical expertise is unavailable. 
Concurrent chemo-radiotherapy seems to provide a survival advantage 
compared with radiotherapy alone. This was demonstrated by the randomised 
controlled trials that informed the NCI’s recommendation to apply concurrent 
Cisplatin-based chemotherapy with radiotherapy in women who require 
radiotherapy for treatment of invasive Ca Cx (NCI 1999). 
 
2.8 CONCLUSION 
 
The evidence in the literature consulted for this study supports the combined use 
of EBRT and ICBT, with HDR-ICBT as an effective treatment modality for FIGO 
stage II and III Ca Cx, as used at DROUAH. The extent to which Cisplatin is used 
as a chemotherapeutic agent in the above-mentioned studies offers a useful 
reference for the current study in terms of efficacy and side-effects. This makes 
possible the benchmarking of the overall outcomes of treatment in terms of the 
general condition of patients, adverse responses to treatment, tumour response 
rates, and quality of life.  
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During the literature review for the current study, which was a continuous 
process, gaps were identified with regard to the availability of studies similar or 
relevant to the current one. This also applies to studies done in the local or 
regional context. The previously conducted studies by Friedrich (1996) and Long 
(2008) at DROUAH are not relevant to the current study. The studies by Friedrich 
(1996) and Long (2008) were conducted to address specific needs that were 
identified in the Department. Similarly, the current study was also inspired by a 
need identified by oncologists at DROUAH.  
 
Studies involving women with Ca Cx and HIV/AIDS continue to be conducted 
throughout the region and the world. The evidence on the adverse effects of 
curative concurrent chemo-radiotherapy treatment for Ca Cx, coupled with the 
compromised defences of HIV+ patients, reinforces local oncologists’ concerns 
about HIV+ patients’ tolerance of the concurrent chemo-radiotherapy protocol for 
Ca Cx at DROUAH. Unfortunately, no evidence of a study exactly similar to this 
one could be found. Although this research gap presents a challenge to the 
objective interpretation of the results of the current study, they do justify the need 
for and purpose of this study. The methodology used in conducting this study is 
discussed in chapter 3. 
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3. CHAPTER 3: MATERIALS AND METHODOLOGY 
 
3.1 INTRODUCTION 
 
The current study was conducted retrospectively at DROUAH, using the records 
of patients treated with radical intent for stage II and III Ca Cx. An analysis of 
patients’ recorded acute and chronic treatment reactions and patients’ general 
health status was done.  
 
This chapter provides background information on the methods and procedures 
followed in conducting the study. The main objective of the study was to 
determine how the HIV+ patients tolerated their treatment. Patients’ treatment 
tolerance was determined by retrospectively analysing their general condition 
and adverse responses to treatment throughout the treatment schedule and for a 
period of 18 months after conclusion of treatment.  
 
The secondary objective was to retrospectively analyse the overall outcomes and 
therapeutic benefits of the treatment in terms of quality of life and tumour 
responses amongst the HIV+ patients. General condition of patients, adverse 
responses to treatment, and tumour responses to treatment were used as 
indicators of overall outcomes and therapeutic benefits of the treatment.  
 
A description is given of the selection of patients, the research tools and methods 
that were applied, and the way in which data was collected and analysed. A brief 
account is also given of the procedures that were involved in acquiring consent to 
conduct the study and to access data contained in patients’ files. In compliance 
with the proposal of the research study, a pilot study was conducted. Details of 
the pilot study are presented in this chapter.  
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3.2 STUDY DESIGN 
 
This project represents an observational study (Schulz and Grimes 2002:616), 
which means that inferences can be drawn about the effect of a specific 
treatment protocol on a selected group of patients, with two different types of 
clinical classification (HIV+ and HIV-). The study was conducted retrospectively, 
using descriptive statistics to describe qualitative data collected from patients’ 
treatment records. Lachin, Matts and Wei (1998:369) define descriptive statistics 
as statistical methods used to summarise or describe a collection of data. The 
data was collected from the patients’ treatment files and captured electronically 
with the aid of a data source sheet. This implies an ex post facto design, because 
previously reported data were analysed (Manion, Cohen and Morrison 
2000:205).  
 
The plan was to offer insight into the effects of a prescribed treatment protocol on 
a selected group of patients (Ca Cx, FIGO stage II and III), treated at DROUAH 
between January 2002 and August 2006. The findings of the current study could 
then be used to review the current approach to treatment of HIV+ patients with 
FIGO stage II and III Ca Cx at DROUAH. Based on the aforementioned 
characteristics, the study can also be classified as exploratory and 
developmental research (Lues, 2009:46). The results of this study are presented 
in chapter 4. 
 
3.3  TREATMENT PROTOCOL  
 
The treatment protocol applicable to this study consisted of a combination of 
EBRT, HDR-ICBT and weekly cycles of chemotherapy given concurrently. EBRT 
in this protocol involved administering 25 daily fractions of 2 Gy (2 Gy / fraction), 
to a total dose of 50 Gy to the whole pelvis. The HDR-ICBT was given weekly on 
days when patients did not receive EBRT. The HDR-ICBT commenced in the 
third week of the treatment schedule, with consecutive weekly fractions in the 
subsequent weeks of treatment. The weekly dosage varied between 2.0 Gy and 
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2.5 Gy per fraction, given in 4-6 fractions. The HDR-ICBT was normalised to the 
highest rectum dose point, to achieve a minimum total dose of 15 Gy to point A. 
Cisplatin was given concurrently as the preferred chemotherapeutic agent. The 
Cisplatin was administered weekly, using doses of 25 mg/m2 per week for 5 
weeks (5 cycles). Patients that were treated using the protocol described in this 
section were patients with FIGO stages II and III, and hence their inclusion in the 
current study. 
 
3.4 ELIGIBILITY 
 
The study was conducted retrospectively, using data recorded in the patients’ 
treatment files. Patients at DROUAH are registered according to their unique 
departmental identification numbers, referred to as the RT-numbers. When a 
patient is registered for the first time at DROUAH, such a patient receives an RT-
number, which serves as the patient’s unique identification number for any 
subsequent visits to the Department.  
 
Before commencing with the study, the departmental statistician at DROUAH 
provided the researcher with a list of patients who were registered in the 
Department with a diagnosis of Ca Cx during the period January 2002 to August 
2006. This list contained the names and RT numbers of 1603 patients. These 
patients’ files had to be accessed and analysed to determine whether they were 
eligible for use in the current study. The inclusion and exclusion criteria are set 
out below. 
 
3.4.1 Inclusion criteria 
1. Patients who received the entire treatment protocol at DROUAH, as set out 
in section 3.3. 
2. Patients with a histologically confirmed diagnosis of Ca Cx, FIGO stage II or 
III. 
3. Histology types: Squamous, Adenocarcinoma, and Adeno-Squamous 
carcinoma of the cervix.  
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4. HIV+ and HIV- patients were eligible for inclusion, and their HIV status had 
to be confirmed and recorded in the files before the commencement of 
treatment.  
5. The follow-up data in patients’ files were reviewed for a maximum follow-up 
period of 18 months, subsequent to conclusion of treatment. 
6. The information in the patients’ files and follow-up records had to be 
available, clear and compliant with the needs of the data source form. 
7. Patients who were registered and recorded as deceased within the 18-
month follow-up period. These records were used to determine mortality 
rates and to establish if any deaths were a consequence of the treatment. 
 
3.4.2 Exclusion criteria  
1. Patients who did not have histological confirmation of Ca Cx, FIGO stage II 
or III. 
2. Patients with a histology type other than Squamous, Adenocarcinoma, or 
Adeno-Squamous carcinoma of the cervix. 
3. Patients with Ca Cx, FIGO stage I or IV. 
4. Patients who were not treated under the protocol set out in section 3.3 
above, or if there was any uncertainty about a patient’s treatment protocol. 
5. Patients whose treatment and follow-up details were missing, unclear, 
incomprehensive, or lacked the information required on the data source 
form. 
 
3.5 RESEARCH TOOL  
 
A preliminary patient data source form (appendix 3) was designed for use as a 
research tool to capture all the necessary data from the patients’ treatment files. 
This form was designed by the researcher after consultations with senior 
oncologists at DROUAH. The questions on the data source form were formulated 
to address the needs identified by oncologists at DROUAH. The preliminary data 
source form was included as part of the research proposal and also served as 
part of the application for ethical approval of the research project. The data 
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source form contained questionnaires to collect information from individual 
patient files. This information can be divided into two main categories, namely 
clinical data and treatment data, based on the needs identified by the researcher 
and the oncologists in the Department.  
 
The clinical data included information on diagnosis, FIGO staging, HIV status, 
CD4 counts, blood counts, and the general condition of the patients. All the 
parameters of patients’ clinical data were presented as options on the data 
source form, which the researcher could select by marking the appropriate 
option.  
 
The treatment data on the data source form included information on the various 
parameters of the treatment the patients received. These parameters included 
patients’ responses to treatment, such as general and physical responses, and 
tumour responses. The information on the treatment the patients received 
included specific details on EBRT, HDR-ICBT and the concurrent chemotherapy 
the patients received, with reference to dose, frequency and overall time.  
 
The researcher could also capture data about patients’ responses to treatment 
by selecting the appropriate options provided on the data source form. This 
selection process would be completed for each parameter of the patient’s 
treatment data on the data source form. Other information that the data source 
form sought related to the acute, early, intermediate and late effects of treatment, 
as well as information recorded during the patients’ follow-up visits, subsequent 
to completion of treatment. If patients received any interventional treatment for 
adverse treatment responses, this was also indicated on the data form.  
 
3.6 PILOT STUDY 
 
A pilot study was conducted to test the data source form for completeness and 
for effectiveness in capturing data logically from the patients’ treatment files. The 
pilot study was executed after ethical approval was granted by the Ethics 
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Committee of the University of the Free State (UFS). As mentioned in section 
3.5, the preliminary data source form was used to capture data from the patients’ 
files. The patients’ files were accessed with the aid of the patient list received 
from the departmental statistician at DROUAH. The researcher retrieved listed 
files from the patient file archive in the department. Patients were selected using 
the criteria outlined in section 3.4.  
 
Twelve patient files deemed eligible in accordance with the inclusion criteria were 
selected for the pilot study. Data from the patients’ files were captured 
electronically on the data source form, using Microsoft Excel®. Each patient’s 
data was captured on a separate Excel worksheet under the headings listed on 
the worksheet, and in accordance with the procedure outlined in section 3.5.  
 
Upon conclusion of the data collection process for the pilot study, the researcher 
had a consultative meeting with a representative from the Department of Bio-
Statistics at the UFS. The purpose of the meeting was to discuss some of the 
challenges identified during the pilot study. Two key challenges were identified 
during the pilot study. The challenges related to the scanty clinical data in the 
treatment files and the practical uses of the preliminary data source form. The 
scanty clinical data in the patients’ treatment files were a consequence of the 
oncologists’ methods of recording data in the patients’ treatment files.  
 
During the pilot study, it was evident that the oncologists did not have a standard 
method of reporting such as the Eastern Cooperative Oncology Group (ECOG) 
performance status system, the European Organisation for Research and 
Treatment of Cancer (EORTC) quality of life module, and the NCI Common 
Toxicity Criteria. The ECOG performance status provides scales and criteria that 
oncologists can use to assess and report on the progress of a patient’s disease, 
how the disease affects the daily life of the patient, and the appropriate treatment 
and prognosis (Oken, Creech, Tormey, Horton, Davis, McFadden and Carbone 
1982:649). The EORTC quality of life module provides oncologists with 
guidelines to report on patients’ quality of life (Jayasekara, Rajapaksa, and 
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Greimel 2008:1053). Oncologists can use the NCI Common Toxicity Criteria to 
report on toxicities that patients incur from treatment they receive (Saibishkumar, 
Patel, Sharma, Karunanidhi, Sankar and Mallick 2005:76). 
 
Discrepancies in the different reports of oncologists were particularly evident in 
the terminology they used and the comprehensiveness of the records. Even 
though the oncologists seemed to have a common understanding of the 
terminology used in the patients’ files, the information was vague, and, in some 
instances, open to interpretation. Some examples of vague and unspecified 
terms are “…patient is doing well…tolerating treatment well…severe 
diarrhoea…weight loss…nausea…blood count too low…swelling…vaginal 
infection…offensive discharge…no tumour…weak…enlarged mass…requires 
hospitalisation…deteriorating…” 
 
Capturing of data on the data source form entailed the selection of options that 
were relevant to the clinical parameters used for the current study. The options 
that could be selected were limited only to the options provided on the data 
source form. These limitations had the potential of placing constraints on data 
collection and analysis. The other challenge was that each patient’s data had to 
be captured on an individual data source form, which was in the form of an MS 
Word® document file. Each document file consisted of at least eight pages, 
which made it difficult for the statistician to capture and manage the large 
volumes of data and information.  
 
Based on the discussions between the researcher and the statistician, a 
collective decision was taken to revise the data source form to create a simpler, 
more practical, more efficient data source form. Several literature sources were 
explored to assist in the compilation of such a data source form. These sources 
included a study conducted by Kim et al. (2007:61), as well as a study conducted 
by Saibishkumar et al. (2005:77). The changes that were made to the data 
source form are discussed in section 3.6.1 below.  
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3.6.1 Revision of the data source form 
Revision of the data source form was intended to address the challenges 
identified in section 3.6 above. The first part of the revision process concerned 
the availability of data in the treatment files. The scanty data in the treatment files 
required the researcher to formulate a reference sheet that could be used for the 
collection of data. The terminology in the patients’ treatment files was used to 
generate an index for the various relevant clinical parameters. These parameters 
were: the general condition of the patient; adverse responses to treatment; and 
tumour responses. Appendix 2 provides an index that was generated for use in 
the collection and analysis of data. The terminology that was commonly used to 
record the oncologists’ reports is also included in the index.  
 
The second part of the revision process concerned the practicality of the form. 
Whereas the original data source form consisted of a detailed questionnaire for 
each patient’s data, the revised data source form (appendix 4) consisted of a 
single data source sheet for all the patients included in the study. The single data 
source sheet was in the form of an Excel® file document, which consisted of two 
worksheets, namely the data-capturing sheet and the index sheet. The data-
capturing sheet was used to capture all the patients’ data from their files and 
transfer it onto the worksheet, with each category of data being captured in the 
designated area provided on the worksheet. The index sheet contained 
descriptions of the codes that were used on the first worksheet. Whereas the 
original data source form contained a textual representation of the required 
clinical and treatment parameters, the revised form was based on a numerical 
coding system.  
 
By means of the coding system, the patients’ treatment and clinical data were 
grouped under various categories, and each category was further grouped into 
clearly defined subcategories. Each subcategory was represented on the data 
source form by a numerical code. Take the example of a patient diagnosed with 
Squamous cell carcinoma. In this case, the data would be recorded under the 
category “diagnosis”, and the “sub-category” would be represented by the 
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numerical code 1, where 1 = Squamous cell carcinoma, 2 = Adeno-carcinoma, 
and 3 = Adeno-squamous cell carcinoma.   
 
Take another example: a patient who completed a full course of chemotherapy. 
In this case, the data would be recorded under the category “chemotherapy”, and 
the “sub-category” would be represented by the numerical code 1, where 1 = 
patient completed the whole prescribed course, and 2 = there were interruptions 
in the administration of chemotherapy during the course of treatment.  
 
The revised data source form was analysed by the researcher and a 
representative from the Department of Bio-Statistics, UFS, to determine whether 
the revised data source form efficiently addressed the previously identified 
challenges. The data that was collected from the pilot study was used to assess 
the revised data source form. The form was accepted and the researcher, 
therefore, could proceed with the data collection process for the main study.  
 
3.7 DATA COLLECTION 
 
The data used for the current study were based on information in patients’ files, 
as recorded by oncologists. Using the list of Ca Cx patients provided by the 
departmental statistician at DROUAH, the RT numbers of patients were used to 
access data.  
 
Once a file was deemed fit for selection in accordance with the inclusion criteria, 
the data were extracted from the file with the aid of the data source form. The 
patients’ clinical and treatment data were captured electronically and presented 
as codes under the different categories and sub-categories provided on the data 
source form, as described in section 3.6.  
 
Through this process, all the files could be accessed, and where there was 
compliance with the inclusion criteria, the data were captured on the data source 
form. The data from all the eligible files were captured on a single worksheet in 
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the Excel® file document that was used as the research tool to collect the data. 
This single Excel® file document was then submitted to the statisticians at the 
Department of Biostatistics at the UFS for processing and analysis.  
 
3.8 STATISTICAL ANALYSIS 
 
All the information and data given to the statisticians at the Department of 
Biostatistics at the UFS were processed and analysed. A sub-analysis of the data 
was also conducted. Based on these analyses, the variables used were 
projected quantitatively in the form of numbers and frequencies. Fisher's exact 
test and the Chi-squared test were used to analyse the data. The results 
obtained by the statisticians were presented to the researcher for final analysis 
and interpretation, in order to formulate inferences and conclusions.  
 
The researcher kept hard copies of all the data that was captured from the 
patients’ files and submitted for analysis. This enabled the researcher to validate 
and verify the analysed data that was received from the statisticians. The 
researcher was also able to refer to the data at any time. The analysis and 
interpretation of these results are discussed in chapter 4. 
 
3.9 ETHICS 
 
The study adhered to all legal and ethical requirements throughout. Consent to 
conduct the study was granted by the Hospital Manager: Clinical Services 
(appendix 5). Consent to conduct the study was granted on condition that no 
patient information was published without the consent of the Chief Executive 
Officer (CEO) of the hospital, Consent to conduct the study was granted on the 
further understanding that the protocol of the study was approved by the Ethics 
Committee of the UFS.  
 
In granting approval for research studies, the Ethics Committee of the UFS 
observes ethical and statutory guidelines that ensure that researchers practice 
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within an established framework of ethical rules and practice. The research 
protocol for this study was submitted to the Ethics Committee of the UFS for 
approval, The study was duly approved on 15 August 2007, ETOVS number 
133/07 (appendix 6).  
 
In addition to the conditions set out for the approval of the current study the 
researcher also sought the advice of colleagues from the Department of 
Biostatistics at the UFS, relating to the disclosure of information relating to the 
HIV status of individuals. The advice from the colleagues from the Department of 
Biostatistics at the UFS led to a decision by the researcher not to include the 
patients’ personal and demographic data on the data source form for this study. 
 
3.10 CONCLUSION 
 
The primary objective of the study was to determine how HIV+ CA Cx patients 
tolerated the radical treatment protocol at DROUAH, with HIV- patients used to 
benchmark the therapeutic benefits in terms of quality of life and tumour 
response. The methods and processes described above were used to conduct 
an analysis of patients’ acute and chronic treatment reactions, as well as their 
general health status during and after treatment. Chapter 4 presents the results 
of radical chemo-radiotherapy in the treatment of Ca Cx at DROUAH.  
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4. CHAPTER 4: RESULTS 
 
4.1  INTRODUCTION 
 
The current study focused on how HIV+ patients tolerated the radical treatment 
protocol for Ca Cx at DROUAH by assessing overall quality of life throughout the 
treatment schedule, and for a maximum period of 18 months after conclusion of 
treatment. Quality of life was assessed by analysing the patients’ general 
condition, and the rate of adverse responses reported. Tumour response was a 
secondary objective, with HIV- patients being used to benchmark the therapeutic 
benefits.  
 
This chapter presents the results of the study. The chapter also presents 
information on patient inclusion procedures, analysis of the patients’ clinical 
information and status at referral for treatment in the Department, as well as 
analysis of the responses of each group of patients for specific variables at 
specific intervals. The variables were the general condition of patients while 
receiving treatment, adverse responses and tumour responses of the patients 
reported during follow-up consultations at specified intervals, after conclusion of 
the treatment protocol.  
 
4.2 STUDY POPULATION 
 
During the planning phase of the current study, a list of all patients registered 
with a diagnosis of Ca Cx for the period 2002 to 2006 was obtained from the 
departmental statistician. This list contained the details of 1603 patients. Patients 
were selected for inclusion in the current study according to the criteria set out in 
sections 3.4.1 and 3.4.2. Accordingly, 111 patients (n = 111) were entered into 
the study.  
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Table 4.1 presents information on the clinical characteristics of the initial study 
population, reflecting the clinical status of patients upon referral for treatment in 
the Department. Aspects of the patients’ clinical status that were analysed 
include diagnosis, FIGO staging and CD4.   
 
Table 4.1 Demographics of the clinical status of the initial study 
population 
 
HIV Negative 
n = 72 (64.9%) 
HIV Positive 
n = 39 (35.1%) Total (n=111) 
Diagnosis (Ca Cx type): 
Squamous Cell  57 (79.2%) 33 (84.6%) 90 
Adenocarcinoma 12 (16.7%) 6 (15.4%) 18 
Adenosquamous  3 (4.1%) 0 (0%) 3 
FIGO Stage: 
II 13 (18.1%) 11 (28.2%) 24 
III 59 (81.9%) 28 (71.8%) 87 
CD4 Count: 
< 100 0 (0.00%) 0 (0.00%) 0 
100 - 200 0 (0.00%) 0 (0.00%) 0 
200 - 400 0 (0.00%) 12 (30.8%) 12 
> 400 72 (100.00%) 27 (69.2%) 99 
 
Although 1603 patients were registered for treatment for Ca Cx at DROUAH from 
January 2002 to August 2006, 647 (40%) patients were treated with radical intent 
for FIGO stage II and III Ca Cx during the aforementioned period. The number of 
patients that were included in the study was 111, representing 7% of the total 
population of Ca Cx patients in the department, and 17% of the total number 
(n=647) of patients treated for Ca Cx with radical intent.  
 
The follow-up data in 339 (52%) of the 647 patients treated with radical intent 
during the period of interest to this study, did not comply with the inclusion criteria 
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for the study. Of the 647 patients treated with radical intent, 77 (12%) patients 
were from the Northern Cape Province. Due to bureaucratic reasons, the follow-
ups for patients from the Northern Cape Province were conducted in Kimberley, 
and these patients’ records could not be used for this study. Sixty-three (10%) of 
the 647 patients treated with radical intent were treated using a different protocol 
to the one of interest in this study, whilst 57 (9%) files were unaccounted for 
during data collection.  
 
4.2.1 Diagnosis 
It is evident that the majority of patients [n = 90 (81.0%)] were diagnosed with 
squamous cell carcinoma. Adenocarcinoma and adenosquamous carcinoma 
were diagnosed in a smaller number of patients [n = 18 (16.2%) and n = 3 
(1.8%), respectively].  
 
4.2.2 FIGO Staging 
In line with the inclusion criteria, only patients with FIGO stage II or III Ca Cx 
were eligible for enrolment in the study. Based on the analysis, it is clear that 
patients were predominantly diagnosed with FIGO stage III [n = 87 (78.3%)].  
 
4.2.3 CD4 Count 
The distribution of patients according to CD4 cell counts made clear that 89.1% 
of patients (n = 99) had a CD4 cell count in excess of 400 CD4 cells per mm of 
blood. The rest [n = 12 (10.9%)] presented with a CD4 count between 200 and 
400 CD4 cells per mm of blood at the commencement of treatment for Ca Cx.  
 
4.3 DATA ANALYSIS 
 
Based on the collected data, the statistician observed that patient data became 
more difficult to come by as patients’ treatment follow-up sessions progressed. 
The decline in data was a consequence of patients who did not honour their 
follow-up appointments as scheduled by the oncologists. The patients’ records 
indicated that patients defaulted on their follow-up appointments at various 
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intervals after completion of the treatment protocol. This tendency was more 
prevalent at longer intervals (12 to 18 months) after completion of treatment. 
Fisher’s exact test was used as the method of choice for the analysis of data, 
with the Chi-squared test being employed in cases where the statistician 
considered data sparse.  
 
A preliminary data analysis conducted by the statistician suggested that there 
was a discrepancy in the composition of HIV+ and HIV- patients in the current 
study. It was evident that some patients commenced with treatment in a good 
general condition while others commenced in a fair general condition. A potential 
consequence was that patients’ general condition at the commencement of 
treatment would be a variable in the analysis of data.  
 
A collective decision was taken by the statistician and the researcher to conduct 
a sub-analysis only on the patients who were in a good general condition at the 
commencement of treatment. The motivation for the decision was to ensure that 
all participants would commence treatment in the same general condition, thus 
eliminating the patients’ general condition as a variable during data analysis. This 
meant that the study population was reduced by 13.5% (from n = 111 to n = 96). 
The number of HIV- patients was reduced by 18% (from n = 72 to n = 59), and 
the number of HIV+ patients by 5% (from n = 39 to n = 37).  
 
The results presented by the statistician were subjected to manual verification by 
the researcher and a senior oncologist. The raw data were collated with the 
analysed data to check that they correlated. The intention of the verification 
process was to make sure that the results were a true reflection of the data 
submitted and to ensure that the results were pure, authentic and valid. 
 
All the results in this chapter reflect the analysis of a total study population of n = 
96. Table 4.2 contains information on the clinical characteristics of the study 
population included in the data sub-analysis. The table represents the patient 
data in the form of numbers, with their percentages in brackets. The number of 
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patients excluded from the initial study population during the sub-analysis is 
presented in brackets as negative numbers in italic font. 
 
Table 4.2 Demographics of the clinical status of the study population 
included in the data sub-analysis 
 
HIV Negative 
n = 59 (61.5%) 
(-13) 
HIV Positive 
n = 37 (38.5%) 
(-2) 
Total (n = 96) 
(-15) 
Diagnosis: 
Squamous Cell Ca 46 (77.9%) (-11) 32 (86.5%) (-1) 78 (-12) 
Adenocarcinoma 10 (17.0%) (-2) 5 (13.5%) (-1) 15 (-3) 
Adenosquamous Ca 3 (5.1%) (-3) 0 (0%) 3 
FIGO Stage: 
II 12 (20.3%) (-1) 10 (27%) (-1) 22 (-2) 
III 47 (79.7%) (-12) 27 (73%) (-1) 74 (-13) 
CD4 Count: 
< 100 0 (0%) 0 (0%) 0 
100 - 200 0 (0%) 0(0%) 0 
200 - 400 0 (0%) 12 (32.4%) 12 
> 400 59 (100%) (-13) 25 (67.6%) (-2) 84 (-15) 
 
 
4.4 TREATMENT RESPONSES 
 
The key objective of the current study was to assess how HIV+ patients tolerated 
the treatment protocol, with the HIV- patients used to benchmark the therapeutic 
benefits in terms of tumour response and general patient condition. Analysis of 
the treatment responses of patients during treatment and shortly thereafter was 
seen as a good indicator of how patients tolerated their treatment.  
 
The study used a maximum follow-up time of 18 months after conclusion of 
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treatment. The 18-month follow-up interval was motivated by information 
obtained from two studies reported in the literature. The first was a retrospective 
analysis of the treatment results of patients with invasive Ca Cx, conducted by 
Saibishkumar et al. (2005:75) in India. The mean follow-up time for overall results 
of treatment was 16.5 months. The second study was conducted by Soeters, 
Bloch, Levin, Dehaeck, and Goldberg (1989:44) and constituted an analysis of 
results obtained by treating patients with chemo-radiotherapy, using Cisplatin, 
Bleomycin and Vinblastine. Fifty-five percent (55.5%) of the patients in this study 
had a median survival time of 20 months. The use of these two studies as a 
benchmark was based on similarities in social, economic, political and cultural 
circumstances that could affect the overall responses of patients. 
 
The sections below provide a summary of the data analysis of patients’ 
responses. Responses throughout the duration of treatment up to a period of 18 
months subsequent to conclusion of the treatment were analysed. The analysis 
focused on the general condition of patients, adverse responses and tumour 
responses. The analysis of general condition, adverse responses and tumour 
responses was related to the chemo-radiotherapy treatment protocol. The weekly 
responses during treatment are dealt with first. 
  
 4.4.1 General condition during treatment  
Patients were examined by oncologists on a weekly basis for the duration of their 
treatment schedule. Records of the weekly consultations were kept in the 
patients’ files. For the purposes of the current study, the data obtained from 
patients’ records focused mainly on their general condition during consultation. 
The researcher grouped the patients’ general condition into five main categories, 
namely good, fair, bad, poor and pre-terminal. The categories for general 
condition are summarised in appendix 2.  
 
Figure 4.1 presents a graphic distribution of the general condition categories for 
the study population of HIV+ and HIV- patients during their seven-week treatment 
schedule.  
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Figure 4.1 General condition during treatment 
 
In the next section, a detailed report, followed by a summary of patient responses 
to treatment during each weekly consultation are presented (see Tables 4.3 to 
4.9).  
 
Week 1: 
All the patients (100%) in the current study were in visibly good general condition 
during the first weekly consultations. Table 4.3 presents the distribution of 
general condition categories for the two groups of patients during the first week 
of treatment. There was no statistically significant difference between HIV+ and 
HIV- patients in terms of general condition in week 1 of treatment (p = 0.057).  
 
 
 
 
 57 
Table 4.3 General condition of patients during week 1 of treatment 
Week 1 
HIV status - + 
Good 100% 100% 
Fair 0 0 
Bad 0 0 
Poor 0 0 
Pre-terminal 0 0 
p-value 0.0572 
 
 
Week 2: 
Almost half (51%) of the HIV+ patients were in good general condition during the 
second week of treatment. Approximately half (53%) of the patients in the HIV- 
group were in fair condition. There was no statistically significant difference 
between HIV+ and HIV- patients in terms of general condition in week 2 of 
treatment (p = 0.096). Table 4.4 presents the distribution of general condition 
categories for the two groups of patients during the second week of treatment.  
 
Table 4.4 General condition of patients during week 2 of treatment 
Week 2 
HIV status - (%) + (%) 
Good 44 51 
Fair 53 35 
Bad 3 14 
Poor 0 0 
Pre-terminal 0 0 
p-value 0.0961 
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Week 3: 
Approximately half (49%) of the HIV+ patients were in fair general condition 
during week 3 of treatment. More than half (58%) of the HIV- patients were in fair 
general condition at the same stage of treatment. There was no statistically 
significant difference between HIV+ and HIV- patients in terms of general 
condition in week 3 of treatment (p = 0.1801). Table 4.5 presents the distribution 
of general condition categories for the two groups of patients during the third 
week of treatment.  
 
Table 4.5 General condition of patients during week 3 of treatment 
Week 3 
HIV status - (%) + (%) 
Good 24 16 
Fair 58 49 
Bad 18 35 
Poor 0 0 
Pre-terminal 0 0 
p-value 0.1801 
 
 
Week 4: 
During the fourth week of treatment, more than two-thirds (70%) of the HIV+ 
group were in bad general condition. Approximately one-quarter (24%) of the 
group were in fair general condition. More than half (54%) of the HIV- group of 
patients were in fair condition during the fourth week of treatment, whilst 
approximately one-third (34%) were in bad general condition. There was no 
statistically significant difference between HIV+ and HIV- patients in terms of 
general condition in week 4 of treatment (p = 0.0024). Table 4.6 presents the 
distribution of general condition categories for the two groups of patients during 
the fourth week of treatment.  
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Table 4.6 General condition of patients during week 4 of treatment 
Week 4 
HIV status - (%) + (%) 
Good 12 6 
Fair 54 24 
Bad 34 70 
Poor 0 0 
Pre-terminal 0 0 
p-value 0.0024 
 
 
Week 5: 
There was an almost equal distribution of reports denoting fair (43%) and bad 
(49%) general condition for HIV+ patients during the fifth week of treatment. Just 
under two-thirds (63%) of HIV- patients were in fair general condition, whilst one-
quarter (25%) were in bad general condition during the fifth week of treatment. 
There was a statistically significant difference between HIV+ and HIV- patients in 
terms of general condition in week 5 of treatment (p = 0.0072). Table 4.7 
presents the distribution of general condition categories for the two groups of 
patients during the fifth week of treatment.  
 
Table 4.7 General condition of patients during week 5 of treatment 
Week 5 
HIV status - (%) + (%) 
Good 10 0 
Fair 63 43 
Bad 25 49 
Poor 2 8 
Pre-terminal 0 0 
p-value 0.0072 
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Week 6: 
There was an equal distribution of reports denoting fair (38%) and bad (38%) 
general condition for HIV+ patients during the sixth week of treatment. 
Approximately one-quarter (24%) of HIV+ patients were in poor general condition 
during the sixth week of treatment. At the same stage of treatment, 
approximately three-quarters (76%) of HIV- patients were in fair general 
condition. There was a statistically significant difference between HIV+ and HIV- 
patients in terms of general condition in week 6 of treatment (p = 0.0001). Table 
4.8 presents the distribution of general condition categories for the two groups of 
patients during the sixth week of treatment.  
 
Table 4.8 General condition of patients during week 6 of treatment 
Week 6 
HIV status - (%) + (%) 
Good 10 0 
Fair 76 38 
Bad 10 38 
Poor 4 24 
Pre-terminal 0 0 
p-value <0.0001 
 
 
Week 7: 
During the seventh week of treatment, approximately half (51%) of HIV+ patients 
were in fair general condition, whilst approximately one-quarter (27%) were in 
bad general condition. At the same stage of treatment, approximately three-
quarters (78%) of HIV- patients were in fair general condition. There was a 
statistically significant difference between HIV+ and HIV- patients in terms of 
general condition in week 7 of treatment (p = 0.0004). Table 4.9 presents the 
distribution of general condition categories for the two groups of patients during 
the seventh week of treatment.  
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Table 4.9 General condition of patients during week 7 of treatment 
Week 7 
HIV status - (%) + (%) 
Good 8 0 
Fair 78 51 
Bad 12 27 
Poor 2 11 
Pre-terminal 0 11 
p-value <0.0004 
 
 
Summary: General condition of patients during treatment 
The results show that the majority of HIV+ and HIV- patients were in fair general 
condition throughout the treatment schedule. During the first four weeks of 
treatment, there were no statistically significant differences between HIV+ and 
HIV- patients. However, in weeks 5, 6 and 7 there were statistically significant 
differences between HIV+ and HIV- patients in terms of general condition   
 
4.4.2 Follow-up consultations 
Once the patients had completed the entire treatment schedule, they were given 
an appointment date for their first follow-up consultation. The date for the first 
follow-up consultation was scheduled three months after completion of the 
treatment protocol. Subsequent follow-up consultations were scheduled at 3-
month intervals for a period of 1 year, following the treatment protocol. After a 
year, the follow-up consultations were scheduled at 6-month intervals. Patients 
were expected to visit the oncologists on the scheduled dates.  
 
During follow-up consultations, the oncologists conducted routine examinations 
of patients, based on clinical examinations, cervical Papanicolaou smears (Pap 
smears), and the information the patients conveyed to them during consultation. 
If the oncologists suspected central or parametrial recurrence during the clinical 
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examination or Pap smears, a biopsy was taken for histological confirmation. The 
information that patients conveyed to the oncologists concerned their general 
well-being, how they felt, and their general health subsequent to treatment. 
 
For the purposes of the current study, the data sought from the patients’ files 
primarily focused on their general condition, tumour responses and adverse 
responses experienced or reported during follow-up consultations. The variables, 
i.e. general condition, adverse responses and tumour response, that were of 
interest during follow-up consultations, are summarised in appendix 2.  
 
During the collection of data, it was observed that in some instances patients did 
not report for their follow-up consultations as scheduled. Some of these patients 
came at a later stage within the scheduled 18-month follow-up period, whilst 
others never came again. In the former case, the records were only used for the 
current study if the follow-up schedule coincided with the schedules prescribed 
for the study. The next section provides information on missing frequency in the 
data analysis. 
 
4.4.2.1 Missing frequency 
In terms of the selection criteria for the study, the follow-up records in the 
patients’ files had to be available, clear and compliant with the needs of the data 
source form. In cases where this criterion was not met these patients were 
excluded from the study. However, there were instances where patients’ data for 
specific follow-up schedules were not available in the files. The data for each 
follow-up schedule was recorded on the data source form as “missing 
frequency”. Two categories of missing frequency were identified and included in 
the study.  
 
The first category included patients who reported for their follow-up consultations 
in line with the prescribed follow-up schedule, but according to the oncologists, 
however, their condition did not justify any further examinations related to tumour 
and/or adverse responses. These patients were, according to the judgement of 
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the oncologists, either pre-terminally ill or had proven progression and were just 
seen for symptomatic interventions or follow-up. The follow-up records of these 
patients were available and up-to-date, except that they did not contain 
information on tumour and/or adverse responses.  
 
The second category included patients who turned up for their follow-up 
consultations, but were outside the schedule prescribed for the study. After 
considering the socio-economic and logistical challenges that patients have to 
contend with, an allowance of 2 weeks on either side of the scheduled follow-up 
date was given for patients to turn up. If patients did not come within the given 
period, their data could not be used for the particular follow-up interval. Patients 
were included in the study because their previous and/or subsequent visits were 
on schedule, and their treatment records were available, clear and compliant with 
the data source form. 
 
The missing frequency categories on all tables and graphs in the current study 
are presented as “no follow-up”; they represent the number of patients for whom 
no data were available at the specific follow-up interval. The “no follow-up” data 
were recorded as a percentage of n = 96, because there was no way to 
determine in what condition the patient would have been at the specified follow-
up interval.  
 
Analysis of the data showed that there was a higher incidence of “no follow-up” 
data amongst the HIV+ patients compared to the HIV- patients. The incidence of 
“no follow-up” data for the HIV+ and HIV- patients, over the 18-month follow-up 
interval were 18% and 12% respectively. The majority of “no follow-up” cases 
were reported in the second half of the 18-month follow-up period, with 
incidences of 73% and 61% for the HIV+ and HIV- patients, respectively.  
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4.4.2.2 General condition of patients at follow-up  
The general condition of patients during follow-up consultations was recorded 
and categorised as good, fair, bad, poor or pre-terminal. The categories for 
general condition during follow-up are summarised in appendix 2. Figure 4.2 
presents a graphic distribution of the general condition of HIV+ and HIV- patients 
during their follow-up visits. The calculation of percentages was based on the 
total number of patients in each group who reported for the scheduled follow-up 
consultations.  
73
27
52
14
33
50
13
4
35
44
17
19
48
26 27
31
11
27
48
17
26
53
21
60
22
9
50
38
43
7
15
61
16
8
0
10
20
30
40
50
60
70
80
Fr
e
qu
e
n
cy
 
o
f r
e
po
rte
d 
co
n
di
tio
n
s 
(%
) 
- + - + - + - + - + - +
3/12 6/12 9/12 12/12 15/12 18/12
Follow-up intervals
General condition at follow-up
No follow-up
Good
Fair
Bad
Poor
Pre-terminal
 
Figure 4.2 General condition at follow-up 
 
Follow-up 1:  3 Months after conclusion of treatment 
A relatively large number (52%) of patients from the HIV+ group were in bad 
general condition, while 27% and 14% of the group were in fair and poor general 
condition, respectively. Most (73%) HIV- patients were in fair general condition. 
There was a statistically significant difference (p < 0.0001) between HIV+ and 
HIV- patients in terms of general condition during this period.  
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Follow-up 2: 6 Months after conclusion of treatment 
Seventy-nine percent (79%) of HIV+ patients were in fair (35%) or bad (44%) 
general condition. Half the HIV- patients were in fair general condition, while one-
third were in good general condition. There was a statistically significant 
difference (p < 0.0001) between HIV+ and HIV- patients in terms of general 
condition for this period. 
 
Follow-up 3: 9 Months after conclusion of treatment 
There was an even distribution of HIV+ patients who were either in bad (31%) or 
poor (31%) general condition, while 27% of patients were in fair general 
condition. Almost half (48%) of the HIV- patients were in fair general condition. 
There was a statistically significant difference (p = 0.0004) between HIV+ and 
HIV- patients in terms of general condition nine months after treatment. 
 
Follow-up 4: 12 Months after conclusion of treatment 
Just over half (53%) of HIV+ patients who turned up for follow-up 12 months after 
treatment were in bad general condition, while just over a quarter (26%) of the 
group were in fair condition. Slightly less than half (48%) of HIV- patients were in 
bad general condition, while just over a quarter (27%) of the group were in fair 
general condition. Twelve months after conclusion of treatment, there was no 
statistically significant difference (p = 0.0064) between HIV+ and HIV- patients in 
terms of general condition.   
 
Follow-up 5: 15 Months after conclusion of treatment 
Half the HIV+ patients were in fair general condition, while just over one-third 
(36%) were in bad general condition. Almost two-thirds (60%) of the HIV- 
patients were in fair general condition. There was no statistically significant 
difference (p = 0.8751) between HIV+ and HIV- patients in terms of general 
condition during this period. 
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Follow-up 6: 18 Months after conclusion of treatment 
Most HIV+ patients were in bad general condition (61%), while smaller numbers 
were in fair (15%) or poor (16%) general condition. Most HIV- patients were in 
bad (43%) or fair (38%) general condition. There was no statistically significant 
difference (p = 0.3561) between HIV+ and HIV- patients in terms of general 
condition 18 months after treatment. 
 
Summary: General condition of patients at follow-up 
The results provide evidence of a specific relationship between HIV+ and HIV- 
patients in terms of general condition. The data related to the general condition of 
patients at follow-up over the designated 18-month period could be interpreted 
with reference to two 9-month periods. During the first 9 months after conclusion 
of treatment, there were statistically significant differences between the two 
groups. Throughout the first 9-month period, most HIV+ patients were in bad 
general condition during their follow-up consultations. Most HIV- patients were in 
fair general condition in the same 9-month period subsequent to conclusion of 
treatment.  
 
During the second 9-month period subsequent to conclusion of treatment, there 
were no statistically significant differences between HIV+ and HIV- patients. At 
each follow-up interval, the highest frequencies of reports for general condition 
were concentrated in the same categories, namely bad and fair, for both HIV+ 
and HIV- patients.  
 
4.4.2.3 Adverse responses at follow-up 
The adverse responses of patients recorded during follow-up consultations were 
categorised into six groups, namely none, moderate, severe, life-threatening and 
death-related. A summary of the categories and a description of adverse 
responses are provided in appendix 2. Figure 4.3 presents a graphic distribution 
of the adverse responses of HIV+ and HIV- patients during follow-up 
consultations.  
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Figure 4.3 Adverse responses at follow-up  
 
Follow-up 1:  3 Months after conclusion of treatment 
Almost half (48%) of the HIV+ patients reported severe adverse responses. The 
majority of HIV- patients (62%) reported moderate adverse responses. There 
was no statistically significant difference (p = 0.0115) between HIV+ and HIV- 
patients in terms of adverse responses for this period. 
 
Follow-up 2: 6 Months after conclusion of treatment 
More than half (54%) the number of HIV+ patients reported moderate adverse 
responses, with one-third (32%) reporting severe adverse responses six months 
after conclusion of treatment. Most HIV- patients reported no (44%) adverse 
responses or moderate (33%) adverse responses. There was no statistically 
significant difference (p = 0.0384) between HIV+ and HIV- patients in terms of 
adverse responses six months after conclusion of treatment.  
 
Follow-up 3: 9 Months after conclusion of treatment 
The majority (79%) of HIV+ patients reported no (35%) adverse responses or 
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moderate (44%) adverse responses nine months after conclusion of treatment. 
The majority (80%) of HIV- patients reported no (41%) adverse responses or 
moderate (39%) adverse responses. There was no statistically significant 
difference (p = 0.8488) between HIV+ and HIV- patients in terms of adverse 
responses nine months after conclusion of treatment.  
 
Follow-up 4: 12 Months after conclusion of treatment 
The majority (86%) of HIV+ patients reported no (65%) adverse responses or 
moderate (21%) adverse responses 12 months after conclusion of treatment. 
Eighty-seven percent (87%) of HIV- patients reported no (54%) adverse 
responses or moderate (33%) adverse responses 12 months after conclusion of 
treatment. There was no statistically significant difference (p = 0.7503) between 
HIV+ and HIV- patients in terms of adverse responses 12 months after 
conclusion of treatment.  
 
Follow-up 5: 15 Months after conclusion of treatment 
Seventy percent (70%) of HIV+ patients reported no adverse responses 15 
months after conclusion of treatment. The majority (71%) of HIV- patients 
reported no adverse responses 15 months after conclusion of treatment. The 
remaining 5% reported life-threatening responses. There was no statistically 
significant difference (p = 0.8982) between HIV+ and HIV- patients in terms of 
adverse responses 15 months after conclusion of treatment.  
 
Follow-up 6: 18 Months after conclusion of treatment 
At the follow-up interval scheduled 18 months after conclusion of treatment, HIV+ 
patients reported no (70%) adverse responses or moderate (30%) responses. 
The majority of HIV- patients reported no (83%) adverse responses, while 7% 
reported moderate adverse responses and 10% reported severe adverse 
responses 18 months after conclusion of treatment. The difference between HIV+ 
and HIV- patients 18 months after conclusion of treatment was not statistically 
significant (p = 0.224).  
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Summary: Adverse responses at follow-up 
Throughout the 18-month follow-up period, there were no statistically significant 
differences between the reports of adverse responses for HIV+ and HIV- 
patients, respectively. A trend similar to the one deduced for the general 
condition of patients at follow-up, is also evident for the data related to adverse 
responses at follow-up.  
 
During the first 3-month period subsequent to conclusion of treatment, the 
majority (48%) of HIV+ patients reported severe adverse responses, while the 
majority (62%) of HIV- patients reported moderate adverse responses. During 
the two subsequent  follow-up intervals, at six and nine months after conclusion 
of treatment, the majority of HIV+ patients reported moderate adverse responses, 
while the majority of HIV- patients reported none. During the last three follow-up 
intervals, at 12, 15 and 18 months, respectively, after conclusion of treatment, 
HIV+ and HIV- patients reported no adverse responses.  
 
4.4.2.4 Tumour responses at follow-up 
The tumour responses of patients recorded during follow-up consultations were 
categorised into six groups, namely total regression, partial regression, no 
response, progression, recurrence and distant metastasis. A summary of the 
categories and a description of tumour responses are provided in appendix 2. 
Figure 4.3 presents a graphic distribution of the tumour responses of the two 
groups of patients during their follow-up visits. Calculation of percentages was 
based on the total number of patients in each group who reported for the 
scheduled follow-up consultations.  
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Figure 4.4 Tumour responses at follow-up 
 
Follow-up 1:  3 Months after conclusion of treatment 
Just more than half (52%) of HIV+ patients who turned up for follow-up 
consultations three months after conclusion of treatment had partial tumour 
regression, while 21% had total tumour regression. More than half the HIV- 
patients showed partial tumour regression, while 36% showed total tumour 
regression, three months after conclusion of treatment. There was no statistically 
significant difference (p = 0.4144) between HIV+ and HIV- patients in terms of 
tumour response three months after conclusion of treatment.  
 
Follow-up 2: 6 Months after conclusion of treatment 
During follow-up interval 2, six months after conclusion of treatment, 50% of HIV+ 
patients had partial tumour regression, whilst 45% had total tumour regression. 
There was an even distribution (45%) of partial and total tumour regression 
among HIV- patients, six months after conclusion of treatment. There was no 
statistically significant difference (p = 0.5033) between HIV+ and HIV- patients in 
terms of tumour response six months after conclusion of treatment.  
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Follow-up 3: 9 Months after conclusion of treatment 
The majority (71%) of HIV+ patients had total tumour regression nine months 
after conclusion of treatment. Just less than two-thirds (64%) of the HIV- patients 
had total tumour regression nine months after conclusion of treatment. There 
was no statistically significant difference (p = 0.5191) between HIV+ and HIV- 
patients in terms of tumour response nine months after conclusion of treatment.  
 
Follow-up 4: 12 Months after conclusion of treatment 
The majority (88%) of HIV+ patients had total tumour regression. Three-quarters 
(75%) of HIV- patients had total tumour regression. There was no statistically 
significant difference (p = 0.6971) between HIV+ and HIV- patients in terms of 
tumour response in this period.  
 
Follow-up 5: 15 Months after conclusion of treatment 
During follow-up interval 5, 15 months after conclusion of treatment, the majority 
(84%) of HIV+ patients had total tumour regression. Just less than three-quarters 
(73%) of HIV- patients had total tumour regression 15 months after conclusion of 
treatment. There was no statistically significant difference (p = 0.6453) between 
HIV+ and HIV- patients in terms of tumour response 15 months after conclusion 
of treatment.  
 
Follow-up 6: 18 Months after conclusion of treatment 
During the last scheduled follow-up interval, 18 months after conclusion of 
treatment, just more than three-quarters (77%) of HIV+ patients had total tumour 
regression. More than three-quarters (78%) of HIV- patients had total tumour 
regression 18 months after conclusion of treatment. There was no statistically 
significant difference (p = 0.1843) between HIV+ and HIV- patients in terms of 
tumour response for this period. 
 
Summary: Tumour responses of patients at follow-up 
Throughout the 18-month follow-up period, there were no statistically significant 
differences between HIV+ and HIV- patients in terms of tumour response. A trend 
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similar to the one deduced for the general condition of patients at follow-up, is 
also evident for the data related to tumour response at follow-up. 
 
The data from the first two follow-up intervals at three and six months, 
respectively, after conclusion of treatment show that most patients had partial 
tumour responses, whilst the data derived from the subsequent follow-up 
intervals, i.e. from 9 to 18 months after conclusion of treatment, suggest that 
most patients showed total tumour regression.  
 
4.4.2.5 Survival 
Out of 96 patients included in the data sub-analysis, there were 19 reported 
deaths, representing an 18-month overall survival rate of 80.2%. Twelve of the 
19 reported deaths were HIV+ patients, whilst the remaining seven were HIV-. 
This implies a 67.6% 18-month overall survival rate for HIV+ patients, and an 
88.1% rate for HIV- patients in the study.  
 
4.5 CONCLUSION 
 
This study analysed the general condition, tumour responses and adverse 
responses of HIV+ and HIV- patients treated for Ca Cx with the same treatment 
protocol. These variables were analysed to assess the patients’ quality of life and 
to determine how HIV+ patients tolerated the radical treatment protocol. Although 
the aim of the current study was not to compare HIV+ and HIV- patients, parallel 
analyses of each group facilitated the drawing of inferences from the results.  
 
Interpretation of data analysis can be tied to the three stages of the schedule the 
study investigated, namely the treatment phase, the first nine months after 
conclusion of treatment, and the second period of nine months after completion 
of treatment. The results and their relevance to the objectives of this study are 
discussed in chapter 5. 
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5. CHAPTER 5: DISCUSSION AND CONCLUSION 
 
5.1  INTRODUCTION 
 
This study retrospectively analysed the treatment responses of HIV+ and HIV- 
patients who received the same treatment for FIGO stage II and III Ca Cx with 
radical intent at DROUAH. The key objective of the current study was to 
determine how the HIV+ patients tolerated their treatment, especially in the light 
of their potentially compromised physiological condition. General condition of 
patients, adverse responses to treatment and tumour responses were used to 
determine overall outcomes and therapeutic benefits of the treatment. The HIV- 
patients were also analysed in order to benchmark the overall outcomes and 
therapeutic benefits of the treatment in terms of quality of life and tumour 
responses, in the absence of physiological challenges. This study (confirmed and 
motivated by a review of applicable sources) was based on the premise that the 
radical chemo-radiotherapy protocol used at DROUAH was the treatment of 
choice for Ca Cx.  
 
The analysis of HIV- patients, therefore, only served as a reference; it was not 
used for the purposes of comparison. This chapter discusses the responses of 
FIGO stage II and III Ca Cx patients to the radical treatment protocol at 
DROUAH. The results regarding HIV+ patients’ tolerance of the radical 
treatment, overall outcomes and therapeutic benefits of the treatment are also 
discussed. The challenges and shortcomings of the study are shared, and 
recommendations made. The study results are discussed next. 
 
5.2 RESULTS OBTAINED FROM THE STUDY  
 
An analysis was made of patients’ general condition, adverse responses to 
treatment and tumour responses. The general condition of patients was analysed 
during treatment and for a short to medium period subsequent to the conclusion 
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of the treatment protocol. The analysis of adverse and tumour responses was 
based on short- to medium-term responses subsequent to the conclusion of the 
treatment protocol. The results concerning the general condition of patients are 
discussed first.  
 
5.2.1 General condition of patients  
The analysis of the general condition of patients was done with reference to two 
phases, namely the immediate term, and the short to medium term. The 
immediate-term analysis was based on patient data recorded during the 
treatment schedule. The short- to medium-term analysis was based on patient 
data recorded during follow-ups, i.e. after patients had completed their treatment. 
The immediate-term analysis was intended to gather evidence on how patients 
tolerated their treatment while they were receiving treatment (Novetsky et al. 
2007:637). On the other hand, it was important to establish how the patients’ 
quality of life was affected by the treatment, and to determine the therapeutic 
benefits of the treatment. This explains the short- to medium-term phase analysis 
of patients’ general condition (Toita et al. 2005:677).  
 
The immediate-term analysis of patients’ general condition shows two different 
trends for the early and late stages of the treatment schedule, respectively. The 
early stages of treatment included weeks 1 to 4 of treatment, while the late 
stages included weeks 5 to 7 of treatment. During the early period of the 
treatment schedule, the HIV+ patients were in good general condition. The HIV+ 
patients’ general condition deteriorated steadily during the first four weeks of 
treatment. During weeks 5 to 7 of treatment, there was a notable deterioration in 
the HIV+ patients’ general condition. During this period, there were no reports of 
HIV+ patients in good general condition. There were no statistically significant 
differences between HIV+ and HIV- patients in terms of general condition during 
the early stages of treatment. However, during the late stages of treatment there 
were statistically significant differences between the two groups.  
 
There were frequent reports of fatigue, dehydration, cystitis, loss of energy, 
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weight loss, anaemia and hypertension. These conditions were suspected to be 
a consequence of the treatment, and, therefore, were regarded as adverse 
responses to the treatment. The frequency and severity of these conditions 
seemed to increase during the later stages (weeks 5 to 7) of the treatment 
schedule.  
 
Analysis of short- to medium-term data indicates that throughout the 18-month 
follow-up period no HIV+ patients were in good general condition. The diagnoses 
regarding their general condition were quite consistent, ranging from bad to fair. 
There were statistically significant differences between HIV+ and HIV- patients 
during the first nine months subsequent to treatment. During the second 9-month 
follow-up period, there were no statistically significant differences between HIV+ 
and HIV- patients in terms of general condition. 
 
Similarly, the follow-up data also showed that the general condition of HIV+ 
patients was better during the second half of the 18-month follow-up period in 
comparison to the first half. Fatigue, dehydration, loss of energy, weight loss, 
anaemia and hypertension were also commonly reported during the follow-up 
analysis. Follow-up data obtained from patients’ files also seemed to suggest an 
increase in the frequency of infectious conditions such as cystitis, flu and 
pneumonia. 
 
The trends observed relating to the general condition of HIV+ patients at follow-
up concur with the assertions of Losso et al. (2000:1616) that it is fairly common 
for the short-term side-effects to continue to get worse for a couple of weeks after 
the treatment, before they get better.  
 
Abraham and Allegra (2001:221) believe there could be a correlation between 
the presence or absence of HIV and the responses of patients to the same 
standard of therapy, with the response to therapy expected to be worse in HIV+ 
patients than in HIV- patients. The current study was inspired by the hunches of 
some oncologists at DROUAH that HIV+ patients showed a poorer tolerance of 
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the radical treatment than their HIV- counterparts. The findings of the current 
study seem to concur with the findings of Abraham and Allegra (2001:221), 
justifying the hunches of oncologists in the Department. 
 
Gallagher (2007:11) lists chronic fatigue and anaemia as some of the 
physiological changes caused by HIV/AIDS, with anaemia having a negative 
impact on the quality of life. Chronic fatigue is one of the most frequent and 
distressing symptoms that people infected with HIV report, and has been 
correlated with decreased quality of life and functional status (Voss et al. 
2006:38). The prevalence of fatigue, dehydration, loss of energy, weight loss, 
anaemia and hypertension could be seen as the result of the combined effect of 
the chemo-radiotherapy the patients received and their HIV/AIDS infection. The 
results of the current study seem to correlate with the results of the two 
aforementioned studies of Voss et al. (2006:38) and Gallagher (2007:11), 
concerning the physiological changes caused by HIV/AIDS and the impact on the 
patients’ quality of life.  
 
The decline in the general condition of HIV+ patients during treatment, and within 
the first 9 months after treatment could be interpreted as a consequence of the 
effects of treatment. This apparent link between the general condition of patients 
and the short- to medium-term effects of the treatment could be interpreted as an 
indicator of patients’ tolerance of the treatment they received. This would imply 
that HIV+ patients did not tolerate their treatment as well as HIV- patients, 
particularly in the immediate and short term. The low tolerance levels among 
HIV+ patients could be attributed to the physiological changes caused by 
HIV/AIDS, such as anaemia and chronic fatigue, which compromise the body’s 
physical strength and defences (Gallagher 2007:11).  
 
5.2.2 Adverse responses to treatment 
The adverse responses to treatment were analysed over a maximum period of 
18 months subsequent to the conclusion of treatment. This was done to 
determine the therapeutic benefits of the treatment and how the patients’ quality 
 77 
of life was influenced by the treatment. There were indications that within the first 
three months subsequent to treatment, a high incidence (48%) of severe adverse 
responses reported by HIV+ patients occurred.  
 
During subsequent follow-ups, a decline was observed in the incidence and 
severity of the adverse responses that were reported. Some of the adverse 
responses that were commonly reported were diarrhoea, dysuria, 
lymphadenopathy, hydronephrosis, cystitis, vaginal stenosis, vaginal infections 
and fibrosis. These side-effects are consistent with those reported in the study 
conducted by Thomas (1999:1199). 
 
The incidence and severity of adverse responses reported by HIV+ patients 
showed a steady decline during the first nine months after treatment, becoming 
stable during the second 9-month follow-up period. The decline in the incidence 
and severity of adverse responses seems to suggest that HIV+ patients were 
recovering from their adverse responses to treatment. During the second nine 
months after treatment, there was a high incidence of “no” adverse responses 
from HIV+ patients, suggesting full recovery from adverse responses to 
treatment.  
 
Throughout the 18-month follow-up period, there were no statistically significant 
differences between HIV+ and HIV- patients. Despite this fact, there were 
indications that HIV- patients had an advantage over HIV+ patients in terms of 
the severity of adverse responses to treatment.  
 
The advantage was seen during the first nine months after treatment. The 
differences in adverse responses between the first and second nine months 
following treatment, were consistent with the general condition of patients during 
follow-ups. These consistencies indicate a relationship between adverse 
responses and the general condition of patients, with the general condition 
improving in step with decreasing incidence of adverse responses. 
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It seems there was a relationship between the general condition of patients and 
their adverse responses, which naturally had an effect on their quality of life. The 
results of the current study support the findings of Abraham and Allegra 
(2001:221) that there could be a correlation between the presence or absence of 
HIV infection and the responses of patients to the same standard of therapy, with 
the response to therapy expected to be worse in HIV+ patients than in HIV- 
patients. There is support for the assertion by Voss et al. (2006:38) that the 
distressing symptoms reported by HIV+ patients, such as fatigue, have been 
correlated with decreased quality of life and functional status.  
 
5.2.3 Tumour responses to treatment 
Tumour responses were analysed with reference to short to medium periods 
following treatment, to determine the therapeutic benefits of treatment based on 
local tumour control. The HIV- patients were used to benchmark the therapeutic 
benefits of treatment in terms of quality of life and tumour response. Beahrs et al 
(1992:156) state that there are variations in tumour sizes between stage II and III 
Ca Cx, with a higher potential of cure in stage II than in stage III tumours. 
However, it was not the focus of the current study to differentiate between tumour 
responses amongst stage II and III tumours.  
 
Within the first six months after treatment, most HIV+ patients showed partial 
tumour regression. During the subsequent follow-ups (from nine to 18 months 
subsequent to treatment), most HIV+ patients showed total tumour regression. 
There were no statistically significant differences between HIV+ and HIV- 
patients throughout the 18-month follow-up period.  
 
The literature consulted for the current study indicates that the treatment 
outcomes for invasive Ca Cx in terms of local tumour control are poorer in HIV+ 
women than in HIV- women, with recurrence rates of up to 88% (Maiman et al. 
1997:79). The results obtained could be interpreted to contradict the findings of 
Maiman et al. (1997:79), implying that the radical treatment protocol for Ca Cx at 
DROUAH offers no added therapeutic benefits to HIV+ patients in terms of 
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tumour responses. However, the results have to be interpreted in the context of 
the limitations and challenges identified during this study. This is discussed in 
section 5.4. The next section provides an overall perspective.  
 
5.3 THE OVERALL OUTCOME OF TREATMENT 
 
The overall outcome or efficacy of cancer treatment is measured by the extent to 
which local tumour control and overall and progression-free survival is improved, 
side-effects are reduced, and quality of life is enhanced (Novetsky et al. 
2007:637). Tolerability of treatment modalities should not be compromised at the 
expense of improvements in the outcome of treatment, and neither should 
improved tolerability be attained at the expense of efficacy (Mitsuyasu 2001:23).  
 
Medical scientists are always trying to use new research and technological 
developments to improve efficacy and enhance the overall outcomes of cancer 
treatment (De Vita et al. 2004:7). The hunches and concerns of local oncologists 
were inspired by and based on principles similar to those outlined by the 
aforementioned authors. The current study, therefore, wanted to address these 
concerns by analysing HIV+ patients’ tolerance of the radical treatment for FIGO 
stage II and III Ca Cx at DROUAH. This analysis was based on the general 
condition of patients, adverse responses to treatment, and tumour responses.  
 
The analyses of the variables related to the treatment of patients provided 
information on the efficacy or overall outcome of the treatment protocol relevant 
to this study. These analyses have been discussed in the preceding sections of 
this chapter. Certain inferences were drawn from the results of the study and the 
literature overview, and were expressed with some caution.  
 
This study had to contend with challenges that could affect the conclusiveness of 
the results. Most of the challenges were the result of logistical and bureaucratic 
limitations. These limitations concerned the study population, the filing system in 
the Department, demographics, socio-economics, and the maximum follow-up 
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period that was used for this study. Challenges were also identified with regard to 
the conditions for ethical approval and the role of anti-retroviral (ARV) treatment. 
The topic of limitations and challenges are discussed in the next section. 
 
5.4 LIMITATIONS AND CHALLENGES IDENTIFIED IN THIS STUDY 
 
The interpretation of this study’s results cannot be done properly without giving 
due consideration to certain limitations. Although 1603 patients were registered 
for treatment for Ca Cx at DROUAH from January 2002 to August 2006, the 
absolute number of patients included in the study was small. A total of 647 
patients were treated with radical intent for FIGO stage II and III Ca Cx during the 
aforementioned period, with only 111 eligible for inclusion in accordance with the 
selection criteria for this study. The 111 patients represent 17.2% of patients who 
were treated for the same condition. The small study population makes the study 
less robust, and the findings need to be tested in studies that are more extensive. 
 
The small study population can be attributed to, among other things, the filing 
system in the Department, demographics, socio-economic factors, and patient 
education and perceptions. DROUAH had a specific strategy for filing patient 
records. However, the success of this system depended on the co-operation of 
both staff members and patients. Clearly, there is a need for a quality control 
system in the filing section to ensure that filing is done in accordance with the 
stipulated protocol.  
 
Demographics also presented some challenges to the data collection process. 
An example of such a challenge concerned the patients referred to the 
Department from the Northern Cape. Inter-provincial bureaucratic policies placed 
serious limitations on follow-up consultations and record-keeping with regard to 
these patients. Follow-up information on Northern Cape patients proved to be 
scanty. Another example of a demographic challenge concerned the patients 
who came from the rural parts of the Free State. Whenever these patients went 
home during treatment, it took a few days before they returned to continue with 
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their treatment. This caused undesirable interruptions in treatment, which, in 
some instances, also led to exclusion from the study.  
 
Socio-economic conditions played a huge role in the well-being of patients. From 
the information in the patients’ files it was noticeable that a considerable number 
of patients were from rural and impoverished parts of the region. Some of these 
patients depended on monthly state grants and financial support. From time to 
time, these patients had to interrupt their treatment to fetch their payouts and 
take care of domestic matters before they could return for treatment. This 
resulted in interruptions in the treatment schedule, which inevitably led to 
extended overall treatment times. In some cases, such interruptions led to 
exclusion from the study.  
 
Patient education and perceptions seemed to have an impact on the patients’ 
general approach to their treatment and follow-ups. Patients who had a 
reasonable understanding of their disease, as well as their need for treatment 
and follow-ups, responded positively to the treatment, specifically in terms of 
completing their treatment schedule and honouring follow-up appointments. The 
responses and the completeness of the data recorded in patients’ files seemed to 
reflect the patients’ level of awareness of the situation they found themselves in. 
Lack of understanding had an impact on patients’ attitude towards their 
treatment, and subsequently on the availability of data in their files. It must be 
borne in mind that, for reasons already discussed, patients’ personal and 
demographic data could not be disclosed. The apparent link between the 
availability of patient data and patients’ social circumstances, therefore, was 
based on practical experience rather than scientific evidence.  
 
The maximum follow-up period of 18 months used in this study, also proved to be 
challenging. Patients’ records indicated that they defaulted on their follow-up 
appointments. Section 4.4.2.1 provides more details on this matter. Patients 
increasingly defaulted on their follow-up appointments as the period after 
conclusion of treatment became longer. This was especially true for the period 12 
 82 
to 18 months after treatment. This meant that data became increasingly sparser 
over the 18-month follow-up period. Naturally, this scarcity of data has an effect 
on the reliability of the study results. 
 
The improvement in the general condition of HIV+ patients during the second 9-
month period following treatment would have been more accurately tested by 
means of a more extensive study with consistently available data throughout the 
envisaged follow-up time schedule. The same rationale is valid for the tumour 
responses. Longer, consistent follow-up schedules would have provided a more 
objective perspective on the tumour responses to treatment. This, in turn, would 
have led to a more accurate analysis of the therapeutic benefits of the treatment 
in terms of tumour control.  
 
There are variations in tumour sizes between stage II and III Ca Cx, with a higher 
potential of cure in stage II than in stage III tumours (Beahrs et al. 1992:156). 
However, the current study did not differentiate between the variations in the 
responses amongst the two stages. In retrospect, this lack of differentiation was 
seen as a shortcoming of this study, because of the possible impact of staging on 
the tumour response rates. Tumour responses were used as a parameter to 
assess the overall therapeutic benefits of the radical chemo-radiotherapy 
treatment protocol in this study. 
  
The data source form initially designed for this study was revised after the pilot 
study. At the beginning, the idea was to collect data via individual questionnaires. 
The revised data source form consisted of a single electronic data source sheet, 
mainly based on a coding system, as described in chapter 3. This data source 
form was used for all patients whose data was eligible for inclusion in the study. 
The coding system used on the data source form relied on clinical data being 
expressed as codes on the source form, with the index for reference purposes.  
 
The clinical data found in patients’ treatment files lacked detail. Data analysis 
depended on what the oncologists recorded in the files, which in turn depended 
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on how they interpreted what their patients communicated to them. Even though 
local oncologists seemed to have a common understanding of the terms they 
used to write their reports, these terms were not uniformly used in line with 
international systems such as the ECOG, EORTC and NCI Common Toxicity 
Criteria. Accordingly, the researcher entered into dialogue with the oncologists 
about the terminology to establish a standard interpretation of the data analysis.  
 
General condition, adverse responses, tumour status and other clinical data 
obtained from patients’ records were expressed as codes without textual 
qualification. The analysis of common toxicities, adverse responses and patient 
complaints recorded in the patients’ treatment records could not be expressed 
qualitatively. The qualitative analysis was based on the descriptions assigned to 
the codes on the data source form.  
 
Compliance with the conditions the Ethics Committee set for approval of this 
project implied that patients’ demographics and personal data could not be used 
for this study. This meant that the impact of patients’ personal circumstances on 
tolerance of treatment, adverse responses and quality of life could not be 
analysed. Matters concerning privacy and confidentiality are sensitive and the 
decision by the Ethics Committee is justifiable.  
 
In November 2003, the Cabinet of the Republic of South Africa approved a 
national plan on HIV/AIDS prevention, care and treatment (Science in Africa 
2004:7). The plan entailed placing 53 000 people on ARV treatment by the end of 
March 2004. As was the case with the treatment protocol relevant to this study, 
there were problems with the implementation of the national plan. In May 2004, 
the President shifted the target date to the end of March 2005, resulting in a one-
year delay in the rollout of the plan (NUMSA, 2004). For this reason, the role of 
ARV’s was not considered in this study.  
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5.5 RECOMMENDATIONS 
 
The need to explore the links between clinical and social matters was expressed 
in preceding sections. However, matters relating to privacy and confidentiality are 
sensitive and need to be protected, as required by and enshrined in the 
Constitution of the Republic of South Africa. The decision by the Ethics 
Committee to protect information relating to patient identity, therefore, is 
justifiable. 
 
Despite the limitations of the data source form, it was useful for the purposes of 
this project, since the aim of the study was to determine tolerance of treatment, 
and not the nature of adverse responses. However, it might be useful for any 
future studies to record and reflect on the extent and nature of adverse 
responses in order to provide qualitative comparisons with findings in the 
literature. In addition, it would be an invaluable innovation to have a standardised 
reference such as the ECOG or EORTC systems for use in the recording of 
patients’ clinical data during follow-ups (Long, Monk, Huang, Grendys, 
McMeekin, Sorosky, Miller, Eaton and Fiorica 2006:539). Future research 
projects will then be based on a standard reporting system in comparison to the 
custom-made index that was designed for this study. 
 
Regarding the study population in this study, follow-up data and the filing system 
were identified as key factors that require attention. The filing system should be 
strictly controlled to ensure adherence to filing protocols. The responsibility of 
filing should not be left solely to the discretion of administrative personnel; other 
health professionals should also be sensitised to the importance of, and the 
adherence to filing protocols. 
 
During data collection there was an evident link between the availability of 
patients’ follow-up data and their socio-economic conditions. It would appear that 
socio-economic problems are prevalent in all societies, and are here to stay. 
However, this problem can be tackled through vigorous and sustained patient 
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education and information programmes. Apart from the possible benefits in terms 
of early diagnosis, such programmes will go a long way towards eliminating 
problems related to treatment interruptions, defaults on follow-up schedules and 
communication with hospital staff to improve on statistics and patient records. 
 
Future research in the field under discussion is encouraged. Future studies 
should consider investigating the role of social factors, such as nutrition and 
social support, particularly in HIV+ patients. The role of highly active anti-
retroviral treatment (HAART), as well as the issue of overall survival rates, should 
also be considered as focus areas. 
 
5.6 CONCLUSION 
 
HIV+ patients treated at DROUAH for FIGO stage II and III Ca Cx with radical 
intent do not tolerate their treatment as well as their HIV- counterparts. The study 
results suggest that the overall quality of life of HIV+ patients was more adversely 
affected than that of HIV- patients, in terms of both general condition and the 
adverse responses that were reported. However, it appears that HIV+ patients 
recovered from the effects of treatment within nine months and showed 
responses similar to those of HIV- patients (where the same standard of therapy 
was used).  
 
The tumour responses of HIV+ patients were analysed, with HIV- patients used 
to benchmark the therapeutic benefits in terms of quality of life and tumour 
response. There were no statistically significant differences between the tumour 
responses of HIV+ and HIV- patients, respectively. However, the therapeutic 
benefits of treatment must be considered in conjunction with the impact of the 
treatment on patients’ overall quality of life. As stated earlier, the results did 
confirm that HIV+ patients showed less tolerance of treatment and poorer quality 
of life due to the adverse effects of treatment than HIV- patients.  
 
Despite the limitations of the study, it appears that the 18-month overall survival 
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rate for HIV- patients was better than that for HIV+ patients, with survival rates of 
67.6% and 88.1% for HIV+ and HIV- patients, respectively. However, the 
objectiveness and validity of these and other findings need to be tested by 
addressing the limitations outlined in section 5.4, and by considering the 
recommendations in section 5.5.  
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7. ABBREVIATIONS 
 
ABS   The American Brachytherapy Society  
AIDS   Acquired Immune Deficiency Syndrome 
AJCC  American Joint Committee on Cancer   
ARV   Anti-retroviral treatment  
Ca Cx  Cancer of the uterine cervix  
CDC   United States Centres for Disease Control  
CIN  Cervical Intraepithelial Neoplasia  
CIS  Carcinoma-in-situ (CIS) 
DROUAH Department of Radiation Oncology - Universitas Annexe hospital, 
Bloemfontein  
EBRT  External beam radiotherapy  
ECOG  Eastern Cooperative Oncology Group   
EORTC  European Organisation for Research and Treatment of Cancer 
FIGO  International Federation of Gynaecology and Obstetrics  
HAART Highly active anti-retroviral treatment 
HDR  High dose-rate   
HDR-ICBT  High dose-rate ICBT  
HIV  Human Immunodeficiency Virus 
HIV-  HIV-negative  
HIV+  HIV-positive  
HPV  Human Papilloma Virus (HPV)  
ICBT   Intra-cavitary brachytherapy  
ICRU  International Commission on Radiation Units and Measurements 
LDR   Low dose-rate  
LDR-ICBT  Low dose-rate ICBT  
NCI  National Cancer Institute  
NUMSA National Union of Metal Workers of South Africa  
OR  Odds ratio or relative risk  
OTT  Overall treatment time (OTT) 
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SIL   Squamous Intra-epithelial Lesion  
STD  Sexually transmitted disease  
TB  Tuberculosis  
U+E  Urea and electrolytes  
UNAIDS  United Nations Joint Programme on HIV-AIDS 
USA  United States of America  
WHO   World Health Organisation  
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8. APPENDICES 
 
Appendix 1: FIGO staging system  
De Vita et al. 2004:887 
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The FIGO Staging System for Ca Cx (De Vita et al. 2004:887) 
 
Stage Description 
I 
Carcinoma that is strictly confined to the cervix; extension to the uterine 
corpus should be disregarded. The diagnosis of both Stages IA1 and IA2 
should be based on microscopic examination of removed tissue, 
preferably a cone, which must include the entire lesion. 
IA 
Invasive cancer identified only microscopically. Invasion is limited to 
measured stromal invasion with a maximum depth of 5 mm and no wider 
than 7 mm.  
IA1 
Stage IA1: Measured invasion of the stroma no greater than 3 mm in 
depth and no wider than 7 mm diameter.  
IA2 
Stage IA2: Measured invasion of stroma greater than 3 mm but no 
greater than 5 mm in depth and no wider than 7 mm in diameter.  
IB 
Stage IB: Clinical lesions confined to the cervix or preclinical lesions 
greater than Stage IA. All gross lesions even with superficial invasion are 
Stage IB cancers.  
IB1 Stage IB1: Clinical lesions no greater than 4 cm in size.  
IB2 Stage IB2: Clinical lesions greater than 4 cm in size. 
 
II 
Carcinoma that extends beyond the cervix, but does not extend into the 
pelvic wall. The carcinoma involves the vagina, but not as far as the lower 
third. 
IIA 
No obvious parametrial involvement. Involvement of up to the upper two-
thirds of the vagina.  
IAB Obvious parametrial involvement, but not into the pelvic sidewall. 
 
III 
Carcinoma that has extended into the pelvic sidewall. On rectal 
examination, there is no cancer-free space between the tumour and the 
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pelvic sidewall. The tumour involves the lower third of the vagina. All 
cases with hydronephrosis or a non-functioning kidney are Stage III 
cancers.  
IIIA 
No extension into the pelvic sidewall but involvement of the lower third of 
the vagina.  
IIIB 
Extension into the pelvic sidewall or hydronephrosis or non-functioning 
kidney. 
 
IV 
Carcinoma that has extended beyond the true pelvis or has clinically 
involved the mucosa of the bladder and/or rectum. 
IVA Spread of the tumour into adjacent pelvic organs. 
IVB Spread to distant organs. 
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Appendix 2: Index: Clinical variables and terminology 
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Index: General condition of patients – during treatment and at follow-up 
Classification Code Description 
Good 1 
Pt visibly in good condition; No complaints1; No medical 
intervention2 required 
Fair 2 
Pt stable; One or two complaints; Minor medical 
intervention required 
Bad 3 
Pt visibly unstable; More than two complaints; More 
intense medical intervention or minor hospitalisation3 
required 
Poor 4 
Deterioration to level requiring more serious 
hospitalisation; Partial interruption4 of treatment protocol 
Pre-terminal 5 
Intense / long-term hospitalisation; Termination5 of 
treatment; or death-related6  
No follow-up 0 
Pt did not report for the scheduled follow-up visit; No 
records for a particular follow-up were available in the 
file; Life status unknown7 
 
The complaints, medical interventions and hospitalisation that were considered 
when categorising the general condition of patients had to be related to the 
chemo-radiotherapy treatment protocol.  
 
1Complaints 
Complaints were regarded as negative aspects, experiences or observations 
relating to treatment that were recorded in the patients’ treatment files. The 
complaints that that were of interest to this study were those that were suspected 
to be a consequence of the chemo-radiotherapy that the patients received. A list 
of complaints was compiled from terminology that was encountered in the 
patients’ files. Complaints that were recorded in patients’ treatment files included 
diarrhoea, dysuria, lymphadenopathy, hydronephrosis, cystitis, vaginal stenosis, 
vaginal infections and fibrosis. Observations that the oncologists noted included: 
patient is doing well; tolerating treatment well; severe diarrhoea; weight loss; 
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nausea; blood count too low; swelling; pelvis feels tender; enlarged inguinal 
glands; vaginal infection; offensive discharge; no tumour; good tumour shrinkage; 
weak; enlarged pelvic mass/es; requires hospitalisation; for admission; and 
deteriorating. 
 
2Medical intervention 
Medical intervention referred to remedial action taken by the oncologists to 
address the complaints of the patients. Interventions varied from minor 
interventions like prescription of medication for mild pain, nausea, diarrhoea. 
More serious intervention required more intense intervention such as intravenous 
infusions for dehydration, blood transfusions for haematological deficiencies or 
referral to other medical specialists for more specialised management. 
 
3Hospitalisation 
Hospitalisation referred to situations where patients were admitted to hospital as 
part of the interventions for their complaints or conditions. Patients were 
hospitalised for various reasons under different conditions. Three different 
categories of hospitalisation are summarised, namely minor-, more serious-, and 
intense/long term hospitalisation. 
 
Minor hospitalisation 
Patients were hospitalised for limited periods where the condition could be 
addressed within a short period of time (1 to 3 days). An example can be 
given where patients were hospitalised for blood transfusion because the 
blood count had dropped to a level that required transfusion. 
 
More serious hospitalisation 
Hospitalisation involved more intense interventions over a longer period of 
time. Examples of such interventions were where patients were hospitalised 
for the treatment of severe infection or skin reaction over a few days (3 to 5 
days). 
 
 107 
Intense / long term hospitalisation 
Hospitalisation involved more intense medical and nursing care over a longer 
term because patients’ general condition had deteriorated to a level where 
they were only capable of limited self-care, confined to bed or chair. 
 
4Interruption  
Instances where patients had to temporarily stop treatment as part of the 
interventions to address the patients’ complaints or conditions.  
 
5Termination 
Instances where patients had to stop treatment. 
 
6Death-related  
Patients had deteriorated to a state where continuation of treatment without 
intense medical care would most probably result in death. In the cases of follow-
ups, patients were categorised as death-related if they were reported or 
suspected to be deceased. A prolonged absence from follow-up consultations 
subsequent to a pre-terminal general condition at the last follow-up was a basis 
for suspicion of death, even though death was not confirmed.  
 
7Life status unknown 
During follow-up some patients did not honour their follow-up schedules. There 
were instances where the patients were in a poor or pre-terminal condition during 
the last follow-up schedule. Some of these patients did not report for their 
subsequent follow-up schedule(s). In such cases the status of these patients was 
recorded as “life status unknown” because it there was no information at the time 
that the follow-up was scheduled. 
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Adverse responses of patients during follow-up consultations 
Classification Code Description 
No follow-up 0 
Pt did not report for follow-up visit, no records in file, life 
status unknown 
No adverse 
responses 
1 No adverse responses to treatment reported 
Moderate 2 
Minor8 responses reported, Require minor medical 
intervention 
Severe 3 
More complex9 responses, Require more intense 
medical intervention, possible minor hospitalisation  
Life-
threatening 
4 
Life-threatening responses, Possible organic 
function/failure, More intense medical intervention, and 
long-term hospitalisation 
Death related 5 
Consequences resulting in death or pre-terminal 
condition 
 
Adverse responses were defined as the negative responses to the chemo-
radiotherapy treatment. These responses included temporary symptoms that 
could interfere with the activities of the patients’ daily lives (Davey et al. 
1999:851).  
 
8Minor responses* 
Responses to treatment result in patients being restricted in physically strenuous 
activity but ambulatory and able to carry out work of a light or sedentary nature, 
e.g., light house work, office work 
 
9Complex responses* 
Capable of only limited self-care, confined to bed or chair more than 50% of 
waking hours 
*ECOG Performance status index (Oken et al. 1982:652).  
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Tumour responses of patients during follow-up consultations 
Classification Code Description 
No follow-up 0 
Pt did not report for follow-up visit, no records in file, life 
status unknown 
Total 
regression 
1 No evidence of tumour or tumour masses present 
Partial 
regression 
2 Reduction in tumour size or mass 
No response 3 No evidence of change in the tumour 
Progression 4 Evidence of progression in tumour size or mass 
Recurrence 5 Tumour has recurred in same area 
Distant 
metastasis 
6 Spread to local or distant areas in the body 
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Appendix 3: Patient data source form – Pilot study 
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Data Source Form – Pilot Project 
 
1.    Clinical Data 
Diagnosis: 
Squamous Cell Ca Adenocarcinoma Adeno-squamous 
 
  
Stage IIA IIB IIIA IIIB 
 
    
HIV Positive Negative 
 
  
CD4 Count Unknown  < 200 200 – 400 > 400 
 
    
RPR Test Positive Negative Unknown  
 
    
 
 
2.    Treatment Data 
External Beam Irradiation (EBRT) – Tick off: 
Central Dose 
(Gy) 
Total 
Fractions 
 
Dose per 
Fraction 
(Gy) 
Total Dose Total Time 
 
2 25 2 50   
      
? Protocol Completed (If not, ? why) 
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HDR Brachytherapy (Microselectron) 
Rectal Dose 
(Gy) 
Min. Dose at 
Point A 
(Gy) 
Total 
Fractions 
 
Total Time 
 
 
      
? Protocol Completed (If not, ? why) 
 
 
Concurrent Chemotherapy - Cisplatin 
Dosage Cycles Total time 
   
? Protocol Completed (If not, ? why) 
 
 
 
3.    CLINICAL NOTES (OBSERVATIONS) 
 
3.1   ACUTE / IMMEDIATE EFFECTS / RESPONSES (EFFECTS DURING TREATMENT) 
GENERAL CONDITION (Short summary) 
 
Blood counts Haemoglb Leuco. Plts. U+E Creat. 
Week 1      
Week 2      
Week 3      
Week 4      
Week 5      
Week 6      
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TUMOUR RESPONSES  
Tumour response Progr.  None Part. Regr. Tot. regr. Mets. 
 
     
If mets – indicate area 
 
ADVERSE RESPONSES 
Response 
Complexity / 
Severity 
Duration Intervention Comments 
 
Nausea / Vomiting      
Fatigue      
Diarrhoea      
Rectum      
Bladder      
Haematol.      
GI       
Other:      
 
     
 
     
 
3.2   EARLY EFFECTS / RESPONSES – < 6 MONTHS FOLLOW-UP 
GENERAL CONDITION (Short summary) 
 
Blood Counts Haemoglb Leuco. Plts. U+E Creat. 
Follow-up 1      
Follow-up 2      
Follow-up 3      
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TUMOUR RESPONSES  
Tumour response Progr.  None Part. Regr. Tot. regr. Mets. 
 
     
If mets – indicate area 
 
ADVERSE RESPONSES 
Response 
Complexity / 
Severity 
Duration Intervention Comments 
 
Nausea / Vomiting      
Fatigue      
Diarrhoea      
Rectum      
Bladder      
Haematol.      
GI       
Other:      
 
     
 
     
 
3.3   INTERMEDIATE EFFECTS / RESPONSES – 7 - 12 MONTHS FOLLOW-UP 
GENERAL CONDITION (Short summary) 
 
Blood Counts Haemoglb Leuco. Plts. U+E Creat. 
Follow-up 1      
Follow-up 2      
Follow-up 3      
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TUMOUR RESPONSES  
Tumour response Progr.  None Part. Regr. Tot. regr. Mets. 
 
     
If mets – indicate area 
 
ADVERSE RESPONSES 
Response 
Complexity / 
Severity 
Duration Intervention Comments 
 
Nausea / Vomiting      
Fatigue      
Diarrhoea      
Rectum      
Bladder      
Haematol.      
GI       
Other:      
 
     
 
     
 
3.4   LATE EFFECTS / RESPONSES – > 12 MONTHS FOLLOW-UP 
GENERAL CONDITION (Short summary) 
 
Blood Counts Haemoglb Leuco. Plts. U+E Creat. 
Follow-up 1      
Follow-up 2      
Follow-up 3      
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TUMOUR RESPONSES  
Tumour response Progr.  None Part. Regr. Tot. regr. Mets. 
 
     
If mets – indicate area 
 
ADVERSE RESPONSES 
Response 
Complexity / 
Severity 
Duration Intervention Comments 
 
Nausea / Vomiting      
Fatigue      
Diarrhoea      
Rectum      
Bladder      
Haematol.      
GI       
Other:      
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Appendix 4: Patient data source form – Revised 
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Patient Data Source Form - Index
0 1 2 3 4 5 6
Diagnosis Squamous Adeno Adeno-squam
Stage IIA IIB IIIA IIIB
HIV Status Negative Positive
CD 4 <100 100 - 200 200 - 400 >400
General Condition - Referral Good Fair Bad Poor Pre-/Terminal
RPR Unknown NEG POS
EBRT Completed Interrupted Stopped
HDRBT Completed Interrupted Stopped
Chemo Completed Interrupted Stopped
General Condition - Weekly Good Fair Bad Poor Pre-/Terminal
General Condition - Follow-up No follow-up Good Fair Bad Poor Pre-/Terminal
Tumour status No follow-up Total regression Partial regression No response Progression Recurrence Distant mets
Adverse effects No follow-up None Mild Moderate Severe Life-threatening Death related
General Condition - Referral Good Fair
Good 1
Fair 2
General Condition - Weekly Good Fair Bad Poor Pre-/Terminal
Good 1 Pt visibly in good condition, No complaints, or medical intervention
Fair 2 Pt stable, with minor complaints, handling treatment well, Minor medical intervention
Bad 3 Pt visibly unstable, with more than two complaints, More intense medical intervention or minor hospitalisation
Poor 4 Deterioration to level of more serious hospitalisation, and partial termination of treatment protocol
Pre-terminal 5 Long-term hospitalisation, termination of treatment, or death-related 
General Condition - Follow-up No follow-up Good Fair Bad Poor Pre-/Terminal
No follow-up 0 Pt did not report for follow-up visit, no records in file, life status unknown
Good 1 Pt visibly in good condition, No complaints, or medical intervention
Fair 2 Pt stable, with minor complaints, handling treatment well, Minor medical intervention
Bad 3 Pt visibly unstable, with more than two complaints, More intense medical intervention or minor hospitalisation
Poor 4 Deterioration to level of more serious hospitalisation, and partial termination of treatment protocol
Pre-terminal 5 Long-term hospitalisation, termination of treatment, or death-related 
Pt visibly in good (healthy) condition. Seems capable of tolerating treatment well. 
Pt in stable condition, Treatment justified.
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0 1 2 3 4 5 6
Tumour Status No follow-up Total regression Partial regressionNo response Recurrence Distant mets
No follow-up 0 Pt did not report for follow-up visit, no records in file, life status unknown
Total regress. 1 No evidence of tumour or tumour masses present
Partial regress. 2 Reduction in tumour size or mass
No response 3 No evidence of change in the tumour
Progression 4 Evidence of progression in tumour size or mass
Recurrence 5 Tumour has recurred in same area
Distant mets 6 Spread to local or distant areas in the body
Adverse Reactions/Responses No follow-up   Mild Moderate Severe Life-threateningDeath-related
No follow-up 0 Pt did not report for follow-up visit, no records in file, life status unknown
None 1 No adverse responses to therapy reported
Moderate 2 Minor responses reported, Require minor medical intervention
Severe 3 More complex responses, Require more intense medical intervention, possible minor hospitalisation, eg. Infusion 
Life-threatening 4 Life-threatening responses, More intense medical intervention, and long-term hospitalisation
Death related 5 Consequences resulting in death or pre-terminal condition
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Appendix 5: Consent - Hospital Manager: Clinical 
Services 
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